https://trial.medpath.com/news/c0488428c86b0e8b/climate-change-extends-pollen-seasons-prompting-new-approaches-to-allergy-management 2025-03-01T10:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/631d505abfffcc2d/high-hdl-cholesterol-linked-to-increased-glaucoma-risk-in-older-adults-large-uk-study-finds 2025-03-01T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5fab217ed38d2bfa/fda-approves-medtronic-s-groundbreaking-adaptive-dbs-system-for-parkinson-s-disease 2025-03-01T05:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/8822818ffa5ef9e3/steakholder-foods-secures-9-25m-in-strategic-funding-to-advance-3d-printed-alternative-proteins 2025-03-01T02:02:24+00:00 hourly 0.9 https://trial.medpath.com/news/39c83da9933d2e53/adagio-medical-restructures-operations-to-focus-on-pivotal-vt-cryoablation-trial 2025-03-01T01:34:14+00:00 hourly 0.9 https://trial.medpath.com/news/4babf7e5a3b0bba7/fda-eliminates-pharmacist-blood-test-verification-requirement-for-clozapine-dispensing 2025-03-01T01:33:28+00:00 hourly 0.9 https://trial.medpath.com/news/149b0c079decb83c/mission-therapeutics-discontinues-preclinical-operations-to-focus-on-advanced-clinical-programs 2025-03-01T01:33:10+00:00 hourly 0.9 https://trial.medpath.com/news/01e897d86a28e742/nice-reverses-decision-approves-sobi-s-altuvoct-for-hemophilia-a-treatment-in-england 2025-03-01T01:32:52+00:00 hourly 0.9 https://trial.medpath.com/news/d07ccccd10f7de1d/fda-issues-new-guidance-on-controlled-correspondence-for-generic-drug-development 2025-03-01T01:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/eba242fa49f65c31/fda-s-march-pipeline-novel-therapies-target-hemophilia-heart-disease-and-rare-conditions 2025-03-01T01:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/38c3c62dbbf1a781/fda-approves-zevtera-for-s-aureus-bacteremia-marking-first-new-treatment-in-15-years 2025-03-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3064f0b0adcd0cc4/navigating-regulatory-hurdles-key-challenges-for-medtech-startups-in-device-development 2025-03-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/332e4ca62fa2ff92/bayer-s-vitrakvi-makes-history-as-first-tumor-agnostic-drug-approved-in-european-union 2025-03-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2216c087e5dc6e98/nice-rejects-takeda-s-fruzaqla-for-advanced-colorectal-cancer-due-to-cost-concerns 2025-03-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7cf121d46bbf5ed4/rocket-pharmaceuticals-gene-therapy-shows-promise-in-early-danon-disease-trial 2025-03-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cc9eadcd34af1e7a/eli-lilly-expands-digital-health-partnership-with-evidation-to-advance-patient-generated-data-analytics 2025-03-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f573bc1e3516509b/expert-insights-navigating-the-complex-landscape-of-biosimilars-and-biobetters-development 2025-03-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/632d3c706bae132d/seismic-therapeutic-s-novel-ige-protease-s-8484-shows-promise-in-preclinical-allergic-disease-studies 2025-02-28T23:02:09+00:00 hourly 0.9 https://trial.medpath.com/news/c8fb408358477eee/kiyatec-secures-cap-accreditation-and-ny-state-approval-for-revolutionary-3d-cancer-diagnostic-platform 2025-02-28T23:01:53+00:00 hourly 0.9 https://trial.medpath.com/news/8d5f676821f9f762/avirmax-biopharma-advances-novel-triple-gene-therapy-for-dry-amd-with-ind-enabling-studies 2025-02-28T22:34:24+00:00 hourly 0.9 https://trial.medpath.com/news/be58892f18c96279/dyne-therapeutics-advances-dmd-treatment-program-despite-price-target-adjustment 2025-02-28T22:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/6ef8ab16c0356706/longeveron-s-lomecel-b-nears-full-enrollment-in-pivotal-hlhs-trial-shows-promise-in-pediatric-heart-disease 2025-02-28T22:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/4ec5c63fedc107e8/bukwang-pharmaceutical-introduces-novel-combination-therapy-for-alzheimer-s-disease 2025-02-28T22:33:25+00:00 hourly 0.9 https://trial.medpath.com/news/1cf28f33b5e1f113/darzalex-r-subcutaneous-regimen-receives-chmp-backing-for-newly-diagnosed-multiple-myeloma-treatment 2025-02-28T22:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/57ed742b3395598b/immune-onc-initiates-phase-i-trial-of-novel-io-108-antibody-for-advanced-hepatocellular-carcinoma 2025-02-28T22:32:41+00:00 hourly 0.9 https://trial.medpath.com/news/5def6a088ca36929/stelara-r-receives-chmp-backing-for-pediatric-crohn-s-disease-treatment-in-europe 2025-02-28T22:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/053fe2a14e5699c5/serina-therapeutics-and-envveno-medical-each-file-100m-mixed-securities-shelf 2025-02-28T22:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/1ec4d4a62ab24ffc/chmp-backs-abbvie-s-rinvoq-for-giant-cell-arteritis-treatment-in-adults 2025-02-28T19:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/cf41265056810760/praxis-therapeutics-essential-tremor-drug-faces-setback-in-phase-3-interim-analysis 2025-02-28T19:34:27+00:00 hourly 0.9 https://trial.medpath.com/news/79149caa88422bfe/sinucleanse-nasal-wash-system-recalled-nationwide-due-to-potentially-fatal-bacterial-contamination 2025-02-28T19:34:08+00:00 hourly 0.9 https://trial.medpath.com/news/952fd95595772c73/koite-health-secures-us-patent-for-technology-enhancing-antibiotic-efficacy-against-superbugs 2025-02-28T19:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/2d3546e0eab17df1/nhs-approves-revolutionary-weekly-treatment-for-severe-haemophilia-a-at-ps510000-per-year 2025-02-28T19:33:36+00:00 hourly 0.9 https://trial.medpath.com/news/44758597b148f17f/ema-and-who-launch-global-pilot-program-to-streamline-drug-regulation-changes 2025-02-28T19:33:17+00:00 hourly 0.9 https://trial.medpath.com/news/05b21f3ca63d2a21/chmp-backs-regeneron-and-novartis-novel-therapies-ahead-of-fda-decisions 2025-02-28T19:32:52+00:00 hourly 0.9 https://trial.medpath.com/news/a4f68e05134cfd1d/dexmedetomidine-shows-no-benefit-in-treating-refractory-septic-shock-pilot-study-finds 2025-02-28T19:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/3d03f57732df1100/cholesterol-drug-fenofibrate-shows-promise-in-treating-hpv-related-cancers 2025-02-28T19:32:13+00:00 hourly 0.9 https://trial.medpath.com/news/df11f08dfe4317a8/ancient-viral-dna-awakens-to-aid-immune-fight-against-kidney-cancer 2025-02-28T19:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/d0c4c02ce86f8eac/bambusa-therapeutics-initiates-phase-i-trial-of-novel-bispecific-antibody-for-alzheimer-s-disease 2025-02-28T19:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/7622df057b7dd783/adocia-secures-eur9-7-million-private-placement-to-advance-diabetes-and-obesity-pipeline-through-q2-2026 2025-02-28T19:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/64bb3935f1cbbb92/eli-lilly-enters-1-6b-molecular-glue-partnership-with-magnet-biomedicine-for-cancer-drug-development 2025-02-28T18:01:58+00:00 hourly 0.9 https://trial.medpath.com/news/f40c0d3e6164603a/praxis-s-phase-3-essential-tremor-drug-trial-faces-futility-concerns-shares-plunge-40 2025-02-28T17:33:06+00:00 hourly 0.9 https://trial.medpath.com/news/866b28b3bd5a42a0/bridgebio-oncology-secures-450m-spac-deal-to-advance-kras-inhibitor-pipeline 2025-02-28T17:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/5f25bbfd3784ed1f/amneal-pharmaceuticals-reports-18-revenue-growth-expands-into-weight-loss-and-biosimilar-markets 2025-02-28T17:32:06+00:00 hourly 0.9 https://trial.medpath.com/news/ccdcad19f2f9b14a/danish-startup-fuse-vectors-secures-5-2m-to-revolutionize-gene-therapy-production 2025-02-28T16:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/4871c4759c9e5b77/alumis-to-present-52-week-phase-2-data-for-novel-tyk2-inhibitor-in-psoriasis-at-aad-2025 2025-02-28T16:35:03+00:00 hourly 0.9 https://trial.medpath.com/news/9fcbe04513a7a99b/three-year-data-shows-sustained-benefits-of-car-t-cell-therapy-in-relapsed-refractory-large-b-cell-lymphoma 2025-02-28T16:34:36+00:00 hourly 0.9 https://trial.medpath.com/news/5e3f6bc4b3eda615/silence-therapeutics-halts-phase-iii-development-of-zerlasiran-seeks-partnership-for-cardiovascular-drug 2025-02-28T16:34:18+00:00 hourly 0.9 https://trial.medpath.com/news/31a3471edd4ef430/thermo-fisher-scientific-acquires-solventum-s-filtration-business-in-4-1-billion-deal 2025-02-28T16:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/faceb671b39cecd2/pds-biotechnology-secures-11-million-in-latest-funding-round 2025-02-28T16:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/014009ecf2a4f694/ema-committee-recommends-new-therapies-including-vyjuvek-for-rare-skin-disease-and-expands-existing-drug-indications 2025-02-28T16:33:28+00:00 hourly 0.9 https://trial.medpath.com/news/9343e1d6b28ef39a/fda-drug-reviews-face-potential-halt-amid-march-2025-government-shutdown-risk 2025-02-28T16:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/6285d492705db50b/phase-4-kinect-pro-trial-shows-ingrezza-significantly-improves-quality-of-life-in-tardive-dyskinesia-patients 2025-02-28T16:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/9d309cc8237e6457/novel-antibiotic-gepotidacin-shows-promise-for-drug-resistant-utis-awaits-fda-review 2025-02-28T16:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/df69bd44cc158d9c/bambusa-therapeutics-initiates-phase-1-trial-of-novel-bispecific-antibody-bbt001-for-atopic-dermatitis 2025-02-28T16:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/a7a5972243c1b487/celldex-advances-barzolvolimab-phase-3-program-in-chronic-urticaria-with-strong-pipeline-progress 2025-02-28T15:03:08+00:00 hourly 0.9 https://trial.medpath.com/news/ae302a8ad7724b83/eisai-partners-with-sciclone-to-expand-tasurgratinib-access-in-greater-china-for-biliary-tract-cancer-treatment 2025-02-28T14:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/5ec25a9cab93d039/dfp-10917-and-venetoclax-combination-trial-advances-to-phase-ii-for-aml-treatment 2025-02-28T14:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/d81aab6a5a8d641e/stanford-expert-outlines-key-strategies-to-enhance-shared-decision-making-in-breast-cancer-care 2025-02-28T14:14:36+00:00 hourly 0.9 https://trial.medpath.com/news/a4302907e143c0a1/nasal-spray-shows-promise-in-treating-traumatic-brain-injury-reducing-inflammation 2025-02-28T14:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/458144348061185d/eu-unveils-major-overhaul-of-pharmaceutical-patent-extension-system-with-centralized-spc-filing 2025-02-28T13:34:41+00:00 hourly 0.9 https://trial.medpath.com/news/ae429c547b947364/abbvie-s-rinvoq-receives-positive-chmp-opinion-for-giant-cell-arteritis-treatment 2025-02-28T13:34:18+00:00 hourly 0.9 https://trial.medpath.com/news/9e5f9c5477350b2b/fda-approves-ind-for-fp008-a-novel-pd-1xil-10m-fusion-protein-for-resistant-solid-tumors 2025-02-28T13:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/eb796b4a92d2b72f/owkin-launches-atlantis-ai-powered-patient-data-mining-initiative-across-20-global-healthcare-centers 2025-02-28T13:33:33+00:00 hourly 0.9 https://trial.medpath.com/news/b3bb61457c11c74d/prorx-pharma-doubles-facility-size-to-combat-critical-drug-shortages 2025-02-28T13:33:17+00:00 hourly 0.9 https://trial.medpath.com/news/df379bafe6db8cac/global-stroke-clinical-trials-landscape-analysis-reveals-key-market-trends-for-2025 2025-02-28T13:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/d131a4257f0ffaef/nk-cell-therapy-market-poised-for-significant-growth-with-innovative-pipeline-developments 2025-02-28T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9462cbe27c48c65a/first-in-human-gene-therapy-trial-launches-for-rare-muscle-disorder-fshd 2025-02-28T11:57:45+00:00 hourly 0.9 https://trial.medpath.com/news/b9e91e9202124caa/viatris-acquires-global-rights-to-cenerimod-for-autoimmune-diseases-with-10m-nxera-deal 2025-02-28T11:32:11+00:00 hourly 0.9 https://trial.medpath.com/news/2fd958883127bb5e/astria-therapeutics-launches-phase-iii-trial-for-novel-hereditary-angioedema-treatment 2025-02-28T10:34:39+00:00 hourly 0.9 https://trial.medpath.com/news/31eb22812ec701c4/renovaro-and-biosymetrics-announce-merger-to-accelerate-ai-driven-drug-discovery-and-biomarker-development 2025-02-28T10:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/6b764db504fa522e/myriad-genetics-partners-with-gabbi-to-expand-hereditary-cancer-risk-testing-access 2025-02-28T10:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/296cdcb40840aaee/emavusertib-shows-promise-in-flt3-mutated-aml-patients-resistant-to-prior-therapies 2025-02-28T10:33:48+00:00 hourly 0.9 https://trial.medpath.com/news/83f860e40e55286e/nxera-pharma-partners-with-holling-bio-pharma-to-launch-daridorexant-for-insomnia-in-taiwan 2025-02-28T10:33:30+00:00 hourly 0.9 https://trial.medpath.com/news/2e91ea4928d93919/biocon-expands-global-footprint-with-launch-of-novel-diabetes-and-obesity-drug-in-uk-market 2025-02-28T10:33:15+00:00 hourly 0.9 https://trial.medpath.com/news/156d0889b218f46f/biocon-pioneers-first-generic-liraglutide-launch-in-uk-for-diabetes-and-obesity-treatment 2025-02-28T10:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/c7429ea3575bd125/foresee-pharmaceuticals-redirects-mirivadelgat-development-to-ph-ild-following-fanconi-anemia-trial-challenges 2025-02-28T10:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/6db3f774e73e77e7/pacific-edge-s-cxbladder-triage-test-incorporated-into-aua-microhematuria-guidelines-as-only-biomarker-with-grade-a-evidence 2025-02-28T10:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/9d4bbe58297e1610/revolution-medicines-novel-drug-shows-promise-in-advanced-pancreatic-cancer-treatment 2025-02-28T09:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/9a9b541bd246f5e8/bullfrog-ai-partners-with-eleison-to-optimize-phase-3-pancreatic-cancer-trial-using-ai-analytics 2025-02-28T09:14:01+00:00 hourly 0.9 https://trial.medpath.com/news/03bc8b92e7f2db57/phase-2-trial-shows-promise-camrelizumab-plus-chemotherapy-effective-for-advanced-nasopharyngeal-cancer-in-non-endemic-regions 2025-02-28T09:13:38+00:00 hourly 0.9 https://trial.medpath.com/news/e5aa337072426c30/phase-4-trial-explores-ozanimod-switch-for-stable-ms-patients-on-anti-cd20-therapy 2025-02-28T09:13:15+00:00 hourly 0.9 https://trial.medpath.com/news/f49707e6d94673ec/fda-approves-five-groundbreaking-treatments-for-ultra-rare-diseases-in-recent-months 2025-02-28T09:12:36+00:00 hourly 0.9 https://trial.medpath.com/news/cb29afb2eef13a4a/experts-highlight-patient-engagement-and-emerging-biomarkers-in-cll-treatment-decision-making 2025-02-28T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f676bf132f1bd455/medigene-and-epimab-partner-to-develop-novel-tcr-guided-t-cell-engagers-for-solid-tumors 2025-02-28T06:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/ebfdabc748ac5a1a/global-polycystic-kidney-disease-clinical-trials-landscape-mapped-in-comprehensive-2025-review 2025-02-28T05:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/27cea2c7ddcf1b41/new-global-clinical-trials-report-reveals-comprehensive-landscape-of-ewing-sarcoma-research-in-2025 2025-02-28T05:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/b4efb33288bd62a5/nccn-awards-three-research-grants-to-advance-gastrointestinal-cancer-treatments-with-taiho-oncology 2025-02-28T05:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/b296e2fe796cdd65/physical-performance-tests-predict-icans-risk-and-survival-in-car-t-cell-therapy-for-nhl 2025-02-28T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/19683f4c23987329/fda-grants-510-k-clearance-to-orthonovis-s-novel-bps-wrist-fracture-system 2025-02-28T05:02:01+00:00 hourly 0.9 https://trial.medpath.com/news/a9f0737f8debdaf6/fda-s-ldt-regulation-faces-uncertainty-as-may-2025-compliance-deadline-approaches 2025-02-28T04:33:29+00:00 hourly 0.9 https://trial.medpath.com/news/004ae289ea07aaf1/scholar-rock-s-phase-iii-trial-advances-apitegromab-development-for-spinal-muscular-atrophy 2025-02-28T04:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/0009483d04c9f944/uk-faces-growing-challenges-in-access-to-rare-disease-medicines-despite-recent-approvals 2025-02-28T04:32:47+00:00 hourly 0.9 https://trial.medpath.com/news/6bcbe7fb1b7f8d9b/imunon-s-dna-plasmid-vaccine-shows-promising-safety-and-immune-response-in-clinical-trial 2025-02-28T04:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/8a250cec4ef1d11f/prestige-af-trial-doacs-show-mixed-results-in-preventing-strokes-for-ich-survivors-with-atrial-fibrillation 2025-02-28T04:32:12+00:00 hourly 0.9 https://trial.medpath.com/news/dd5f4ba616cc75ae/uk-experts-call-for-centralized-genomic-database-to-accelerate-rare-disease-trial-recruitment 2025-02-28T03:18:58+00:00 hourly 0.9 https://trial.medpath.com/news/8b9a9d1eb308587b/afynia-secures-5m-to-advance-novel-blood-test-for-faster-endometriosis-diagnosis 2025-02-28T02:31:50+00:00 hourly 0.9 https://trial.medpath.com/news/3df6ddccc5f770f1/soleno-therapeutics-advances-toward-potential-dccr-approval-for-prader-willi-syndrome-with-strong-financial-position 2025-02-28T02:01:26+00:00 hourly 0.9 https://trial.medpath.com/news/8933b6005ac87fc5/testosterone-recovery-after-adt-shows-46-lower-mortality-risk-in-high-risk-prostate-cancer-study 2025-02-28T01:33:29+00:00 hourly 0.9 https://trial.medpath.com/news/a64115dd3a763f44/fda-clears-tandem-s-control-iq-algorithm-for-type-2-diabetes-management 2025-02-28T01:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/58cab633ebf7f8b1/higher-dose-fractionated-reirradiation-shows-promise-in-recurrent-high-grade-glioma-treatment 2025-02-28T01:32:47+00:00 hourly 0.9 https://trial.medpath.com/news/e633f8b73161b2b2/early-biological-therapy-shows-promise-in-young-psoriasis-patients-belgian-study-supports-step-down-approach 2025-02-28T01:32:27+00:00 hourly 0.9 https://trial.medpath.com/news/b46bffd99dfa09c9/calliper-trial-in-progressive-ms-shows-distinct-patient-profile-with-lower-inflammatory-activity 2025-02-28T01:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/bb09cd5f6de5191f/novel-triple-immunotherapy-approach-shows-promise-in-glioblastoma-treatment 2025-02-28T01:31:48+00:00 hourly 0.9 https://trial.medpath.com/news/e7a3b0ac2a3fb0d0/myriad-genetics-partners-with-pathomiq-to-advance-ai-powered-prostate-cancer-prognosis-platform 2025-02-28T01:31:26+00:00 hourly 0.9 https://trial.medpath.com/news/6aa4f60dac751ef7/fda-initiates-review-of-roche-s-monthly-injectable-crovalimab-for-rare-blood-disorder-pnh 2025-02-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/42ef7d9006e3b0f2/topical-drug-delivery-market-set-to-reach-454-93-billion-by-2031-as-targeted-delivery-technologies-advance 2025-02-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fbca57a5e7e93158/work-medical-and-shanghai-chartwell-form-strategic-alliance-to-advance-high-end-medical-technologies 2025-02-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0801106dd4007903/fda-approves-soliris-for-refractory-myasthenia-gravis-first-new-treatment-in-60-years 2025-02-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/14b07085cd70c617/swissmedic-approves-46-new-active-substances-in-2024-marking-12-increase-in-drug-authorizations 2025-02-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9bf5bb4746bc6eab/daiichi-sankyo-and-alteogen-partner-on-300m-deal-to-develop-subcutaneous-enhertu 2025-02-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/84677adfaa171901/merck-ceo-calls-for-pharma-industry-reputation-rebuild-amid-public-trust-crisis 2025-02-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0bbb175932232923/latin-america-s-pharmaceutical-market-access-challenges-and-opportunities-in-emerging-markets 2025-02-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d2eadb15d3adee10/digital-revolution-reshapes-healthcare-rise-of-the-patient-of-the-future-drives-innovation 2025-02-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/03069fed8cd3bd38/fda-accepts-review-of-lerodalcibep-for-ldl-cholesterol-reduction 2025-02-27T23:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/9c8baa9097bf8979/breathe-biomedical-initiates-major-clinical-trial-for-innovative-breast-cancer-breath-test 2025-02-27T23:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/24c089040665978e/ribociclib-letrozole-combo-shows-promising-24-response-rate-in-low-grade-serous-ovarian-cancer-trial 2025-02-27T22:34:25+00:00 hourly 0.9 https://trial.medpath.com/news/69192dc777338c97/estee-lauder-partners-with-serpin-pharma-to-develop-anti-inflammatory-skincare-technology 2025-02-27T22:34:08+00:00 hourly 0.9 https://trial.medpath.com/news/cb8a68fffee4dcd2/fda-clears-arcuro-medical-s-superball-rc-system-for-rotator-cuff-repair-enhancement 2025-02-27T22:33:49+00:00 hourly 0.9 https://trial.medpath.com/news/07db61a94b7bf7ce/eli-lilly-announces-27-billion-investment-in-four-new-us-manufacturing-sites 2025-02-27T22:33:29+00:00 hourly 0.9 https://trial.medpath.com/news/fd6b459fbd678345/fda-expands-odactra-r-approval-for-house-dust-mite-allergy-treatment-to-include-young-children 2025-02-27T22:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/f4f0d98090a52484/structure-therapeutics-advances-oral-obesity-drug-programs-with-completed-enrollment-in-key-aleniglipron-trials 2025-02-27T22:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/0e85b090cd05dc54/pharmala-to-develop-novel-mdma-dosage-form-for-military-ptsd-trial-at-ut-health-san-antonio 2025-02-27T22:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/572d5429dc747a34/across-global-alliance-adopts-wemedoo-s-oomnia-platform-to-transform-global-clinical-trial-management 2025-02-27T22:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/40bb7a0192e5b573/advancing-rare-disease-research-primary-data-collection-studies-emerge-as-critical-tool-for-real-world-evidence 2025-02-27T22:31:47+00:00 hourly 0.9 https://trial.medpath.com/news/fbe0fa020180c244/validose-secures-2m-pre-seed-funding-to-transform-clinical-trial-adherence-with-smart-drug-delivery-platform 2025-02-27T22:31:28+00:00 hourly 0.9 https://trial.medpath.com/news/0a6b5d91947d8617/advancing-rare-disease-research-how-mrna-technology-and-synthetic-control-arms-are-transforming-clinical-trials 2025-02-27T21:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/4962653ae5791829/fda-removes-ozempic-and-wegovy-from-shortage-list-sparking-legal-challenge-from-compounding-groups 2025-02-27T20:01:50+00:00 hourly 0.9 https://trial.medpath.com/news/c165ebd3e00de172/phase-3-trial-shows-superior-immunogenicity-of-rabies-booster-after-zagreb-regimen-compared-to-essen-protocol 2025-02-27T19:35:09+00:00 hourly 0.9 https://trial.medpath.com/news/dacf0105105d7817/usda-grants-conditional-approval-for-zoetis-avian-influenza-vaccine 2025-02-27T19:34:50+00:00 hourly 0.9 https://trial.medpath.com/news/ffac8b30863807b2/ema-evaluates-fast-track-status-for-three-novel-therapeutics-from-scholar-insmed-and-soleno 2025-02-27T19:34:35+00:00 hourly 0.9 https://trial.medpath.com/news/57a461a477b52e07/fda-cancels-critical-flu-vaccine-advisory-meeting-raising-production-timeline-concerns 2025-02-27T19:34:21+00:00 hourly 0.9 https://trial.medpath.com/news/06960a5c134768ec/wegovy-s-market-dominance-grows-with-expanded-cardiovascular-indication-and-strong-clinical-results 2025-02-27T19:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/8af0cdb04ba42d4b/recursion-exscientia-merger-signals-new-era-in-ai-driven-drug-discovery 2025-02-27T19:33:37+00:00 hourly 0.9 https://trial.medpath.com/news/4916006767ed7507/ira-price-controls-threaten-u-s-small-molecule-drug-innovation-and-clinical-research 2025-02-27T19:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/394aef28e7762251/aspire-biopharma-goes-public-on-nasdaq-through-spac-merger-to-advance-fast-absorbing-aspirin-development 2025-02-27T19:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/bebf2a4fc2bfddc2/fda-inspection-of-emcure-s-api-facility-results-in-form-483-relonchem-gains-uk-approval-for-pain-relief-combination 2025-02-27T19:32:47+00:00 hourly 0.9 https://trial.medpath.com/news/3d29ac53be7319ab/major-pharmaceutical-companies-advance-novel-seizure-treatments-with-promising-pipeline-developments 2025-02-27T19:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/c35921b162a989ca/iavi-and-biofabri-launch-phase-2a-trial-of-novel-tuberculosis-vaccine-in-adults-and-adolescents 2025-02-27T19:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/3abc74742041cf50/first-patient-receives-novel-outlast-enhanced-car-t-therapy-for-advanced-kidney-cancer 2025-02-27T19:31:47+00:00 hourly 0.9 https://trial.medpath.com/news/0d0084e40d70d1c5/retinalgenix-launches-revolutionary-remote-ocular-monitoring-system-for-early-disease-detection 2025-02-27T19:31:30+00:00 hourly 0.9 https://trial.medpath.com/news/75fc5e08685b613d/hhs-reviews-moderna-s-590m-bird-flu-vaccine-contract-amid-market-uncertainty 2025-02-27T19:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/cdfd4959b2b2f6d6/multiple-sclerosis-trial-analysis-comorbidities-increase-risk-of-treatment-discontinuation-and-adverse-events 2025-02-27T18:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/b7e01636673f739e/novavax-pivots-business-model-shifts-focus-from-vaccine-development-to-technology-licensing 2025-02-27T18:01:38+00:00 hourly 0.9 https://trial.medpath.com/news/7a62a38cc67ebf7e/medtronic-partners-with-brainomix-to-advance-ai-powered-stroke-care-solutions 2025-02-27T16:35:38+00:00 hourly 0.9 https://trial.medpath.com/news/bfd04a261ca7f147/brainomix-and-medtronic-form-strategic-alliance-to-transform-stroke-care-with-ai-technology 2025-02-27T16:35:24+00:00 hourly 0.9 https://trial.medpath.com/news/49d7989eb1a27f4f/zevra-therapeutics-secures-150m-deal-for-rare-pediatric-disease-priority-review-voucher 2025-02-27T16:35:10+00:00 hourly 0.9 https://trial.medpath.com/news/7f7731f38e9d11b9/hbm-alpha-therapeutics-secures-395m-licensing-deal-for-novel-cah-treatment 2025-02-27T16:34:50+00:00 hourly 0.9 https://trial.medpath.com/news/877fda495a957c3d/tiximed-reports-positive-safety-data-from-first-cohort-in-phase-1-trial-of-novel-type-1-diabetes-drug-tix100 2025-02-27T16:34:08+00:00 hourly 0.9 https://trial.medpath.com/news/3241cd50ae18d082/usaid-funding-freeze-disrupts-critical-hiv-vaccine-development-in-africa 2025-02-27T16:33:52+00:00 hourly 0.9 https://trial.medpath.com/news/bcd1f81748c39dad/fda-grants-fast-track-status-to-avb-114-novel-cell-therapy-for-crohn-s-perianal-fistulas 2025-02-27T16:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/4585c83f073a2f99/major-advances-in-angioedema-pipeline-intellia-s-gene-therapy-enters-phase-3-as-multiple-companies-race-for-novel-treatments 2025-02-27T16:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/95b6e1f4f0816e54/fda-approves-google-pixel-watch-3-s-novel-pulse-detection-feature-for-critical-health-monitoring 2025-02-27T16:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/fb15e16e091eee86/canopy-growth-expands-german-medical-cannabis-portfolio-with-tweed-brand-launch 2025-02-27T16:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/3437602325c063a3/esmo-endorses-hlb-s-cam-rivo-for-first-line-liver-cancer-treatment-ahead-of-fda-decision 2025-02-27T16:32:16+00:00 hourly 0.9 https://trial.medpath.com/news/67bbfed4d2a192a2/bevacizumab-biosimilars-demonstrate-comparable-efficacy-and-safety-profile-to-avastin-in-advanced-nsclc-study 2025-02-27T16:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/9beb4c5497cc6338/vapor-2-trial-completes-enrollment-testing-novel-water-vapor-ablation-device-for-prostate-cancer 2025-02-27T16:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/880ba3b99c883e84/virpax-pharmaceuticals-reports-successful-human-trial-of-molecular-envelope-technology-with-no-severe-adverse-events 2025-02-27T15:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/51874bab249bc82a/adagene-initiates-phase-2-trial-of-novel-ctla-4-inhibitor-in-early-stage-colorectal-cancer 2025-02-27T14:31:43+00:00 hourly 0.9 https://trial.medpath.com/news/a58a8832759ea5c2/zeiss-visumax-800-with-smile-pro-receives-nmpa-approval-for-laser-vision-correction-in-china 2025-02-27T14:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/0d8d635099fd2af3/cost-effectiveness-analysis-critical-for-optimizing-car-t-and-bispecific-therapies-in-blood-cancers 2025-02-27T14:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/87c45f9634bbc196/tango-therapeutics-tng462-receives-orphan-drug-status-for-pancreatic-cancer-as-company-advances-prmt5-inhibitor-programs 2025-02-27T14:01:59+00:00 hourly 0.9 https://trial.medpath.com/news/5436a3de076173e3/glenmark-launches-generic-epinephrine-injection-with-180-day-exclusivity 2025-02-27T13:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/d2ae856606979169/aspargo-labs-strengthens-leadership-team-with-appointment-of-former-amgen-regulatory-expert-as-cro 2025-02-27T13:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/024c79f4d062eab2/divesiran-shows-promise-in-phase-1-2-trial-for-polycythemia-vera-treatment 2025-02-27T13:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/4c5d9c9f73a908c7/philippine-senator-urges-fast-track-approval-of-takeda-s-tak-003-dengue-vaccine-amid-56-case-surge 2025-02-27T13:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/67532e554ee7191a/fda-grants-fast-track-status-to-bluerock-s-novel-cell-therapy-for-inherited-retinal-diseases 2025-02-27T13:31:28+00:00 hourly 0.9 https://trial.medpath.com/news/8213006b28d32538/higher-radon-exposure-linked-to-37-increased-risk-of-gestational-diabetes-in-first-time-pregnancies 2025-02-27T13:07:10+00:00 hourly 0.9 https://trial.medpath.com/news/82154d39aaf4729b/eu-streamlines-clinical-trial-regulations-with-single-portal-system-to-accelerate-drug-development 2025-02-27T12:46:50+00:00 hourly 0.9 https://trial.medpath.com/news/9daf1ddf5df46511/redhill-biopharma-reports-strong-start-to-2025-with-strategic-partnerships-and-commercial-growth 2025-02-27T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/53e9438e1abbf712/vantage-secures-fda-drug-master-file-for-vycerintm-api-glycerin-enhancing-pharmaceutical-formulation-options 2025-02-27T11:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/29d451f3b23c09fc/u-s-healthcare-cro-market-projected-to-reach-29-68-billion-by-2034-growing-at-7-1-cagr 2025-02-27T11:41:52+00:00 hourly 0.9 https://trial.medpath.com/news/2276898fae6b3964/landmark-study-shows-60-of-critical-nicu-infants-should-receive-rapid-genome-sequencing 2025-02-27T11:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/548034c17eb7a2d4/nanoform-reports-strong-growth-and-advances-in-nanoparticle-drug-development-pipeline 2025-02-27T10:31:46+00:00 hourly 0.9 https://trial.medpath.com/news/a75bded40d3ad3fe/fda-grants-priority-review-for-gamifant-in-hlh-mas-associated-with-still-s-disease 2025-02-27T10:31:25+00:00 hourly 0.9 https://trial.medpath.com/news/7643c2a1eb1f8e92/dsmb-endorses-continuation-of-phase-3-dragon-trial-for-tinlarebant-in-stargardt-disease 2025-02-27T08:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/bda60133625bdf97/ai-investment-in-clinical-operations-set-to-surge-industry-leaders-project-2b-spending-by-2028 2025-02-27T08:04:09+00:00 hourly 0.9 https://trial.medpath.com/news/1a3d656ffb027179/iteos-secures-120m-funding-to-advance-tigit-antibody-program-in-nsclc 2025-02-27T08:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/089b31a9ecfd724b/novel-approaches-transform-lymphoma-treatment-landscape-from-genomic-profiling-to-liquid-biopsies 2025-02-27T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d410ee67b5bd54d7/fluoguide-advances-phase-ii-head-and-neck-cancer-trial-following-successful-clinical-results 2025-02-27T07:34:23+00:00 hourly 0.9 https://trial.medpath.com/news/ca4d79796a552fc2/lightlake-therapeutics-reports-phase-ii-success-for-novel-binge-eating-disorder-nasal-spray-treatment 2025-02-27T07:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/a18a6e25633fa03e/oncoinvent-completes-safety-lead-in-cohort-enrollment-for-novel-alpha-radiation-therapy-in-ovarian-cancer-trial 2025-02-27T07:31:34+00:00 hourly 0.9 https://trial.medpath.com/news/07baf29a3ea001a8/surgery-shows-superior-outcomes-over-sabr-in-elderly-nsclc-patients-study-finds 2025-02-27T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/14e1fda09d9b5ba1/fda-approves-miudella-first-new-copper-iud-in-four-decades-expands-contraceptive-options 2025-02-27T04:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/8119183e37efae2b/rapid-micro-biosystems-and-merck-kgaa-sign-five-year-global-distribution-agreement-for-growth-direct-system 2025-02-27T04:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/57065b07b0df4ca2/ge-healthcare-launches-flyrcado-revolutionary-pet-imaging-agent-for-coronary-artery-disease 2025-02-27T01:32:22+00:00 hourly 0.9 https://trial.medpath.com/news/7af90a7880639b13/medtronic-launches-global-trial-for-prevail-drug-coated-balloon-in-coronary-artery-disease 2025-02-27T01:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/553ae878c24f7399/fda-approved-itovebi-combination-for-advanced-breast-cancer-requires-careful-blood-sugar-monitoring 2025-02-27T01:31:43+00:00 hourly 0.9 https://trial.medpath.com/news/0a8f06531794da94/uab-launches-comparative-study-of-dorzagliatin-vs-standard-therapies-for-type-2-diabetes-night-time-glucose-control 2025-02-27T01:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/64776242fd0c0b61/fda-approves-phathom-s-novel-h-pylori-treatments-securing-260m-financing-for-launch 2025-02-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/968660bfdf63a85f/thermo-fisher-scientific-launches-comprehensive-sle-registry-to-address-critical-research-gaps 2025-02-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/98421c17fb8d9314/fda-approvals-of-lecanemab-and-donanemab-spark-divided-response-among-healthcare-professionals 2025-02-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/44d808dac4962321/puma-biotechnology-acquires-takeda-s-aurora-kinase-inhibitor-alisertib-for-7m-upfront 2025-02-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c05dacfe499870cc/jazz-pharmaceuticals-acquires-global-rights-to-zanidatamab-in-1-76-billion-deal-with-zymeworks 2025-02-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/742eabccb2ba1411/relay-therapeutics-to-launch-phase-3-trial-for-rly-2608-in-advanced-breast-cancer-mid-2025 2025-02-26T23:02:14+00:00 hourly 0.9 https://trial.medpath.com/news/b2e18e95a6a6fa15/pharnext-s-cmt1a-drug-pxt3003-fails-to-meet-primary-endpoint-in-phase-3-premier-trial 2025-02-26T23:01:22+00:00 hourly 0.9 https://trial.medpath.com/news/7934b824e42bc48e/kiniksa-reports-strong-arcalyst-growth-advances-kpl-387-for-recurrent-pericarditis-development 2025-02-26T22:32:10+00:00 hourly 0.9 https://trial.medpath.com/news/c2daa2c07a572d52/loxo-435-shows-promise-as-selective-fgfr3-inhibitor-in-metastatic-urothelial-cancer-trial 2025-02-26T22:31:50+00:00 hourly 0.9 https://trial.medpath.com/news/f5071a89a65d2066/single-dose-of-antenatal-steroids-shows-progressive-benefits-for-extremely-preterm-infants 2025-02-26T22:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/e8673b10d2c2c168/experts-debate-value-of-ctdna-testing-in-muscle-invasive-bladder-cancer-management 2025-02-26T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d76d7b67a91174de/icad-and-koios-medical-unite-to-launch-comprehensive-ai-powered-breast-cancer-detection-platform 2025-02-26T20:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/0253eecee851bd33/ligand-pharmaceuticals-leads-75m-royalty-financing-for-d-fi-gene-therapy-in-rare-skin-disease-trial 2025-02-26T20:01:22+00:00 hourly 0.9 https://trial.medpath.com/news/2b9b57bc3a0db1fe/cargo-therapeutics-halts-cd22-cell-therapy-trial-sparks-debate-on-biotech-company-survival 2025-02-26T19:32:06+00:00 hourly 0.9 https://trial.medpath.com/news/fd410f38c71ff6e2/novel-screening-technologies-enter-clinical-trial-to-detect-silent-esophageal-precancer 2025-02-26T19:31:41+00:00 hourly 0.9 https://trial.medpath.com/news/94aedc0df41f90b9/nih-funded-best-icu-trial-explores-behavioral-economics-to-enhance-critical-care-bundle-implementation 2025-02-26T19:31:26+00:00 hourly 0.9 https://trial.medpath.com/news/0a0204c5e31f4864/immunocore-reports-strong-kimmtrak-sales-growth-and-advances-clinical-pipeline-in-2024 2025-02-26T17:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/c232a56ea8450fab/one-year-study-shows-sustained-benefits-of-arc-ex-therapy-in-spinal-cord-injury-patients 2025-02-26T17:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/6a661c443ed0192c/federal-court-rejects-novartis-challenge-to-medicare-drug-price-negotiation-program 2025-02-26T17:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/6a50d34072321196/nielsen-biosciences-completes-phase-3-enrollment-for-novel-wart-treatment-candin 2025-02-26T16:33:27+00:00 hourly 0.9 https://trial.medpath.com/news/d81064693653d0f7/eu-clinical-trials-regulation-takes-full-effect-as-life-sciences-sector-embraces-digital-transformation 2025-02-26T16:33:06+00:00 hourly 0.9 https://trial.medpath.com/news/b15cd2d9e35fbce0/eikon-therapeutics-secures-351m-series-d-funding-to-advance-melanoma-treatment-to-phase-iii 2025-02-26T16:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/0f64c77543d12aa2/oncohost-and-gustave-roussy-launch-premis-study-to-predict-immunotherapy-side-effects 2025-02-26T16:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/90fe418182374529/abcuro-secures-200m-series-c-to-advance-phase-ii-iii-trial-for-rare-muscle-disease-treatment 2025-02-26T16:32:14+00:00 hourly 0.9 https://trial.medpath.com/news/421b753b3181a4ac/zervimesine-shows-promise-in-geographic-atrophy-trial-building-on-success-in-multiple-cns-disorders 2025-02-26T16:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/a150a98383ef83cf/fda-clears-ind-for-adcendo-s-novel-tissue-factor-targeting-adc-in-advanced-solid-tumors 2025-02-26T16:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/ce60a74cdb6bf2ff/xanomeline-trospium-shows-promising-cognitive-benefits-in-schizophrenia-patients-with-baseline-impairment 2025-02-26T15:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/a3305d4e015f626c/immunoprecise-and-ribopro-form-strategic-alliance-to-advance-mrna-driven-antibody-discovery 2025-02-26T14:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/78a035eaea3d6b03/fda-grants-fast-track-status-to-pyxis-oncology-s-pyx-201-for-advanced-head-and-neck-cancer 2025-02-26T14:31:28+00:00 hourly 0.9 https://trial.medpath.com/news/8c9ef5ee69b12c9c/bipartisan-epic-act-seeks-to-eliminate-ira-s-small-molecule-drug-development-disincentive 2025-02-26T14:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/70099c1c2102e112/imunon-s-dna-vaccine-shows-promising-immune-response-against-covid-19-in-phase-1-trial 2025-02-26T14:01:45+00:00 hourly 0.9 https://trial.medpath.com/news/2dc809e6eecc756e/assembly-bio-initiates-phase-1a-trial-of-first-in-class-oral-hdv-entry-inhibitor-abi-6250 2025-02-26T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2450b5ce75256c54/wellgistics-partners-with-tollo-health-to-address-glp-1-side-effects-and-long-covid-through-medical-foods 2025-02-26T13:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/89331e12a033b73f/novel-technologies-show-promise-in-amd-treatment-gene-therapy-and-light-based-interventions-take-center-stage 2025-02-26T13:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/e011b2d443a0bd95/imetelstat-shows-promise-in-mds-and-myelofibrosis-treatment-new-ash-data-reveals 2025-02-26T13:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/34b98ddea19e4ab6/fda-grants-fast-track-status-to-opus-genetics-eye-drop-treatment-for-night-vision-impairment 2025-02-26T13:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/282dfa3277ef3e09/innocare-s-orelabrutinib-shows-over-90-reduction-in-ms-brain-lesions-in-phase-ii-trial 2025-02-26T13:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/ef192771472436d7/kangpu-s-novel-molecular-glue-modulator-kpg-818-receives-ind-approval-in-china-for-multiple-myeloma-treatment 2025-02-26T13:32:14+00:00 hourly 0.9 https://trial.medpath.com/news/8008f84e7fc92ba9/aspire-biopharma-advances-high-dose-sublingual-aspirin-development-following-successful-feasibility-study 2025-02-26T13:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/8079f7f67b544957/mtbvac-tb-vaccine-enters-landmark-phase-2b-trial-across-three-african-countries 2025-02-26T13:31:30+00:00 hourly 0.9 https://trial.medpath.com/news/50efed8f4ab30461/geron-reports-strong-q4-2024-results-with-47-5-million-in-rytelo-revenue-expects-profitability-without-additional-financing 2025-02-26T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/df6dc97e50170730/fda-grants-510-k-clearance-to-abanza-s-washercaptm-mini-for-meniscal-root-repair-and-acl-reconstruction 2025-02-26T12:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/b6404034c5c018c1/enodia-therapeutics-launches-with-novel-protein-degradation-platform-targeting-cancer-and-inflammatory-diseases 2025-02-26T12:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/d30157daff8b1d20/leading-oncologists-share-critical-insights-on-managing-adc-therapies-in-clinical-practice 2025-02-26T12:12:06+00:00 hourly 0.9 https://trial.medpath.com/news/237a19320aea9c94/experts-call-for-ecosystem-wide-approach-to-address-disparities-in-stem-cell-therapy-access 2025-02-26T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f31021b330bf99d2/trump-administration-overhauls-healthcare-policy-major-cuts-to-medicaid-rfk-jr-confirmed-as-hhs-secretary 2025-02-26T10:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/22f5fd1eb6719db9/first-patient-dosed-in-novel-breast-cancer-trial-combining-wee1-inhibitor-with-trodelvy 2025-02-26T10:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/85f18be9deaab97d/ignota-labs-secures-6-9m-to-revive-failed-drug-candidates-using-ai-platform 2025-02-26T08:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/1640411087c9f487/kestra-medical-technologies-launches-ipo-aims-to-raise-140-160-million-for-cardiovascular-wearable-technology 2025-02-26T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d69853c9f4d2da68/springworks-gomekli-approval-showcases-new-model-for-rescuing-shelved-rare-disease-drugs 2025-02-26T06:45:32+00:00 hourly 0.9 https://trial.medpath.com/news/c03bd7ffa58ccd2e/fda-approval-of-axatilimab-marks-new-era-in-chronic-gvhd-treatment 2025-02-26T06:12:03+00:00 hourly 0.9 https://trial.medpath.com/news/45710594849633f6/usaid-funding-freeze-threatens-global-clinical-trials-and-infectious-disease-research 2025-02-26T04:35:55+00:00 hourly 0.9 https://trial.medpath.com/news/14174c2a0ae11f25/mobocertinib-fails-to-outperform-chemotherapy-in-first-line-egfr-exon-20-nsclc-trial 2025-02-26T04:32:02+00:00 hourly 0.9 https://trial.medpath.com/news/5035dddd030f90c2/triastek-s-3d-printed-drug-d23-shows-promising-targeted-delivery-for-iga-nephropathy-treatment 2025-02-26T04:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/30cd53acb543d4bf/galcanezumab-shows-significant-promise-in-first-randomized-trial-for-vestibular-migraine-treatment 2025-02-26T04:31:26+00:00 hourly 0.9 https://trial.medpath.com/news/7aa2f491475a5e5c/eli-lilly-acquires-organovo-s-fxr-agonist-program-for-ibd-in-60m-deal 2025-02-26T03:38:23+00:00 hourly 0.9 https://trial.medpath.com/news/4566413871f6c973/terns-pharmaceuticals-advances-cml-drug-tern-701-and-obesity-treatment-tern-601-in-clinical-trials 2025-02-26T02:31:46+00:00 hourly 0.9 https://trial.medpath.com/news/bf35fdb119197918/alnylam-plans-three-major-phase-iii-trials-in-2025-for-attr-amyloidosis-and-hypertension 2025-02-26T01:31:50+00:00 hourly 0.9 https://trial.medpath.com/news/22f2fedaf67e81c6/breakthrough-drug-for-feline-heart-disease-rapamycin-shows-promise-in-reversing-hcm 2025-02-26T01:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/678638145dc38da8/inovalon-launches-ai-powered-platform-to-transform-clinical-trial-patient-recruitment 2025-02-26T01:21:05+00:00 hourly 0.9 https://trial.medpath.com/news/13c2c767f53891e6/allogene-and-foresight-diagnostics-forge-37-3m-partnership-for-lymphoma-diagnostic-development 2025-02-26T00:01:21+00:00 hourly 0.9 https://trial.medpath.com/news/040334a374db5844/china-approves-first-in-class-tenapanor-for-hyperphosphatemia-in-dialysis-patients 2025-02-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ad2e727cf81c4614/gt-biopharma-secures-0-7m-through-strategic-warrant-exercise-for-trike-r-platform-development 2025-02-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/77c352bc8a8d1258/fda-clears-tidepool-loop-first-iphone-controlled-automated-insulin-dosing-app-for-type-1-diabetes 2025-02-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bdc72e35b5694846/north-carolina-emerges-as-global-bioscience-hub-with-2-5b-international-investment-surge 2025-02-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5ce2e528b18b5d1f/fda-expands-rare-disease-research-support-with-27-million-in-grants-and-new-innovation-hub 2025-02-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c24ca2bb28c9574a/priavoid-completes-recruitment-for-phase-ii-alzheimer-s-drug-trial-of-pri-002 2025-02-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/568f9c475b5e76e0/biomerica-secures-eu-ivdr-certification-for-food-intolerance-diagnostics-targeting-ibd-patients 2025-02-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7b18d75b0f181bd6/microbiotica-reveals-novel-mechanisms-of-microbiome-enhanced-immunotherapy-response-with-mb097 2025-02-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f3c5f6a990f48e95/actio-biosciences-advances-precision-medicine-platform-for-rare-and-common-diseases 2025-02-25T23:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/f525f61fe977394f/phase-iii-trial-success-ferumoxtran-shows-promise-in-detecting-small-prostate-cancer-metastases 2025-02-25T23:01:24+00:00 hourly 0.9 https://trial.medpath.com/news/e10d09dda0129258/ecopipam-shows-breakthrough-results-in-phase-3-trial-for-tourette-syndrome-treatment 2025-02-25T22:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/97d39fae825d2d03/fda-accepts-review-of-uzedy-for-bipolar-i-disorder-treatment-extension 2025-02-25T22:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/7b2070a84f8c42bd/cooling-therapy-shows-no-benefit-for-preterm-infants-with-brain-injury-nih-study-finds 2025-02-25T22:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/1b79ddd9ea0871bb/elanco-s-credelio-quattro-breaks-new-ground-in-multi-parasite-protection-for-dogs 2025-02-25T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7af1c7ae21f53627/ai-powered-wearable-device-shows-97-accuracy-in-predicting-epileptic-seizures 2025-02-25T21:01:27+00:00 hourly 0.9 https://trial.medpath.com/news/e31b6312f97b1ca7/cema-cel-shows-promising-2-year-durability-data-in-large-b-cell-lymphoma-treatment 2025-02-25T20:01:26+00:00 hourly 0.9 https://trial.medpath.com/news/ba147fa86a48c4b5/phase-iii-trial-shows-superior-efficacy-of-preservative-free-latanoprost-emulsion-for-glaucoma-treatment 2025-02-25T19:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/500df0e3b21204de/breakthrough-bone-marrow-transplant-shows-88-cure-rate-for-sickle-cell-disease 2025-02-25T19:32:07+00:00 hourly 0.9 https://trial.medpath.com/news/c426798e4d69bb90/ai-powered-facial-analysis-technology-enters-clinical-trials-for-depression-screening 2025-02-25T19:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/7dcf3b9b67b94409/england-leads-with-nhs-coverage-of-wegovy-and-mounjaro-for-obesity-while-australia-delays 2025-02-25T19:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/733a23ab387978fa/agilus-diagnostics-partners-with-lucence-to-bring-advanced-cancer-liquid-biopsy-testing-to-india 2025-02-25T18:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/1d8b64a4265ae29b/fulcrum-s-pociredir-scd-trial-advances-with-key-data-readouts-expected-in-2025 2025-02-25T18:03:20+00:00 hourly 0.9 https://trial.medpath.com/news/227e86e76362c565/novel-sonodynamic-therapy-demonstrates-promising-safety-and-efficacy-in-glioblastoma-treatment 2025-02-25T18:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/caf3f805c23f2bcf/harmony-biosciences-reports-strong-q4-2024-results-outlines-pipeline-milestones-for-2025 2025-02-25T17:02:18+00:00 hourly 0.9 https://trial.medpath.com/news/7f38936f32e2f997/biological-e-s-14-valent-pneumococcal-vaccine-shows-promise-in-phase-3-trial 2025-02-25T16:34:41+00:00 hourly 0.9 https://trial.medpath.com/news/2c8366a9af18aba5/fda-grants-breakthrough-therapy-status-to-radiprodil-for-grin-related-seizure-treatment 2025-02-25T16:34:19+00:00 hourly 0.9 https://trial.medpath.com/news/32801f29fc4b2968/nexobrid-shows-superior-results-in-phase-iii-pediatric-burn-treatment-study 2025-02-25T16:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/753ba6fb64a65c34/psilocybin-assisted-therapy-shows-promise-in-small-fibromyalgia-trial 2025-02-25T16:33:31+00:00 hourly 0.9 https://trial.medpath.com/news/135eb3f03527fb27/healey-center-launches-als-mymatch-program-to-accelerate-early-phase-drug-development 2025-02-25T16:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/5b914329b2386a92/fembloc-non-surgical-birth-control-shows-100-effectiveness-in-clinical-trials-with-five-year-safety-data 2025-02-25T16:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/514cdfd4906073bc/cdr-life-and-boehringer-ingelheim-s-geographic-atrophy-treatment-advances-to-phase-2-clinical-trials 2025-02-25T16:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/1dd995cfb3652107/northwestern-s-lurie-cancer-center-joins-clinical-trial-testing-lixte-s-lb-100-plus-dostarlimab-for-ovarian-clear-cell-cancer 2025-02-25T16:32:22+00:00 hourly 0.9 https://trial.medpath.com/news/c29dfc50d1c4a9aa/theralase-s-rutherrin-shows-promise-in-non-hodgkin-s-lymphoma-treatment-when-combined-with-metformin-and-radiation 2025-02-25T16:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/fb1b9017b0966454/enveric-biosciences-secures-patent-for-novel-non-hallucinogenic-compounds-targeting-addiction-and-adhd 2025-02-25T16:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/7adc1b0c35368beb/vivici-secures-eur32-5m-series-a-to-launch-fermentation-derived-lactoferrin-in-2025 2025-02-25T15:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/a9736dbe759e99b6/camrelizumab-plus-chemotherapy-shows-promise-in-cervical-cancer-treatment-with-100-disease-control-rate 2025-02-25T14:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/9bff4056402a84f9/ryvu-therapeutics-restructures-operations-to-extend-cash-runway-prioritizes-rvu120-blood-cancer-program 2025-02-25T13:33:05+00:00 hourly 0.9 https://trial.medpath.com/news/2ea6cc700a5fc5f2/cognition-therapeutics-reveals-promising-biomarker-strategy-for-alzheimer-s-treatment-patient-selection 2025-02-25T13:32:47+00:00 hourly 0.9 https://trial.medpath.com/news/72076a00e3dbedde/venus-remedies-and-infex-therapeutics-partner-to-develop-novel-antibiotic-resistance-fighter-met-x 2025-02-25T13:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/b2e17f99590b246c/eli-lilly-expands-zepbound-weight-loss-drug-access-with-new-doses-and-lower-cash-prices 2025-02-25T13:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/f43b4fb19de3ff07/lag-3-immunotherapies-market-poised-for-explosive-growth-with-next-generation-therapies-advancing-across-major-markets 2025-02-25T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/81b715bf9b847e0a/miltenyi-biotec-launches-india-s-first-cell-gene-therapy-center-of-excellence-in-hyderabad 2025-02-25T12:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/512fa215a0dde8a2/sterotherapeutics-launches-phase-2-trial-of-novel-cushing-s-syndrome-treatment-st-002 2025-02-25T11:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/aa05d569602d664f/fda-approves-protocol-for-cambium-bio-s-phase-3-trial-of-elate-ocular-in-dry-eye-disease 2025-02-25T10:33:17+00:00 hourly 0.9 https://trial.medpath.com/news/6c11104c46831aa3/mankind-pharma-advances-novel-oral-anti-obesity-drug-in-phase-2-trials 2025-02-25T10:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/2650ba6f929028c6/study-reveals-16-of-phase-2-cancer-trial-patients-receive-eventually-fda-approved-drugs 2025-02-25T10:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/a700e3fd9f1e6286/verana-health-and-nanoscope-partner-to-leverage-70000-patient-database-for-retinitis-pigmentosa-gene-therapy-research 2025-02-25T10:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/5263d9dff89acba2/ai-powered-technology-shows-promise-in-rx-to-otc-drug-transition-study-reports-petros-pharmaceuticals 2025-02-25T09:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/b1f16853fed752f5/first-patient-treated-with-eshunt-system-in-landmark-nph-trial-marking-new-era-in-hydrocephalus-treatment 2025-02-25T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1b5273bb09d0e1e4/monument-therapeutics-raises-ps850k-to-advance-novel-schizophrenia-cognitive-treatment-mt1988 2025-02-25T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/2082f3e7b73653cf/bridgene-and-takeda-form-770m-alliance-to-tackle-undruggable-targets-in-neurology-and-immunology 2025-02-25T08:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/3d081aa99d7607d2/grade-guidelines-reinforce-intranasal-corticosteroids-as-first-line-therapy-for-chronic-rhinosinusitis-with-nasal-polyps 2025-02-25T08:00:50+00:00 hourly 0.9 https://trial.medpath.com/news/1a756d3cd3521bed/study-reveals-critical-gap-less-than-1-of-us-clinical-trials-include-pregnant-participants 2025-02-25T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/940c2c1c079715da/swog-s1815-nab-paclitaxel-addition-to-standard-chemotherapy-under-investigation-for-advanced-biliary-tract-cancer 2025-02-25T07:33:01+00:00 hourly 0.9 https://trial.medpath.com/news/b37db85096ca9f27/ema-expands-lanadelumab-approval-with-new-subcutaneous-dosing-options-for-hae-patients 2025-02-25T07:32:47+00:00 hourly 0.9 https://trial.medpath.com/news/4a8666d5832ed614/fda-issues-refuse-to-file-letter-for-wakix-in-idiopathic-hypersomnia-treatment 2025-02-25T07:32:33+00:00 hourly 0.9 https://trial.medpath.com/news/cb32cc4c97c2ab35/korean-hospitals-secure-approval-for-sk-biopharmaceuticals-cenobamate-for-epilepsy-treatment 2025-02-25T07:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/b874bd626f5a1a98/fda-grants-breakthrough-device-designation-to-averto-medical-s-coloseal-system-for-ostomy-free-colorectal-surgery 2025-02-25T06:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/559a7be4a685c886/veloxis-pharmaceuticals-transplant-candidate-vel-101-receives-official-name-pegrizeprument 2025-02-25T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b9eb553f72ef45b1/first-brain-directed-gene-therapy-upstaza-receives-eu-recommendation-for-rare-aadc-deficiency 2025-02-25T05:01:18+00:00 hourly 0.9 https://trial.medpath.com/news/0c126cce4058d7ca/limited-uptake-of-core-outcome-set-in-coronary-artery-disease-trials-despite-2015-standardization-effort 2025-02-25T04:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/f46b16216d0f2c2a/scripps-research-develops-long-acting-injectable-version-of-anti-malaria-drug-atovaquone 2025-02-25T04:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/7219c004f49f4313/alnylam-unveils-ambitious-pipeline-and-platform-innovation-at-r-d-day 2025-02-25T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/080ef62d3ca3b4af/pharmaceutical-industry-rallies-behind-diversity-in-clinical-trials-despite-regulatory-uncertainty 2025-02-25T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8b00d3286cef216f/dcgi-mandates-safety-data-submission-for-two-legacy-combination-drugs-within-3-months 2025-02-25T03:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/258d43fe6ca2f8f3/novel-triple-immunotherapy-combination-shows-promise-in-pd-1-resistant-gastroesophageal-cancer 2025-02-25T01:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/a964c989ae76a99e/chilean-rsv-vaccine-advances-to-phase-2-clinical-trials-in-europe-targeting-elderly-population 2025-02-25T01:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/613ce2c198acf32f/fda-rejects-poziotinib-for-her2-mutated-nsclc-following-advisory-committee-s-negative-vote 2025-02-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a34afc30560b3815/enveric-biosciences-secures-patent-for-novel-evm401-compounds-targeting-mental-health-treatment 2025-02-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c2d61b72880bf693/china-adds-90-innovative-drugs-to-national-reimbursement-list-boosting-access-to-cancer-and-rare-disease-treatments 2025-02-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8c9b2f7d1151b76b/epicore-biosystems-secures-32m-in-expanded-series-b-for-advanced-sweat-sensing-wearable-technology 2025-02-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/853859b63316b45b/carsgen-partners-with-zhuhai-sb-xinchuang-to-advance-allogeneic-car-t-development-in-china 2025-02-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0221c0c90f5bf96a/evolutionaryscale-launches-with-142m-to-transform-drug-discovery-using-advanced-ai-protein-platform 2025-02-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b298847e669c53e0/novel-mrna-delivery-system-bypasses-liver-for-targeted-ibd-treatment 2025-02-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/155c46052fea3a00/carb-x-awards-2-million-to-immunethep-for-novel-e-coli-vaccine-development 2025-02-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cc6577ad6b0ba40e/orasis-pharmaceuticals-prepares-for-march-launch-of-fda-approved-presbyopia-eye-drop-qlosi 2025-02-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a67110cedcce6783/glenmark-pharmaceuticals-reaches-7m-settlement-in-us-antitrust-lawsuits-over-cholesterol-drugs 2025-02-24T22:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/eca464e331fe5334/fda-denies-invivyd-s-eua-expansion-request-for-covid-19-antibody-pemgarda 2025-02-24T22:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/4da1f6534fb43468/hemogenyx-initiates-first-human-dosing-of-car-t-therapy-for-resistant-acute-myeloid-leukemia 2025-02-24T22:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/3c473e6e2e00fea5/study-reveals-ozempic-s-potential-as-depression-treatment-in-landmark-analysis 2025-02-24T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c3519200635a40f6/chmp-recommends-enhertu-r-approval-for-her2-low-ultralow-metastatic-breast-cancer-in-eu 2025-02-24T20:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/320b719c32754181/fda-grants-priority-review-to-roche-s-lunsumio-for-follicular-lymphoma-treatment 2025-02-24T19:33:22+00:00 hourly 0.9 https://trial.medpath.com/news/6eea124a15dfc498/darolutamide-falls-short-in-phase-ii-trial-for-ar-positive-triple-negative-breast-cancer 2025-02-24T19:33:05+00:00 hourly 0.9 https://trial.medpath.com/news/6880bdec013c16dd/therapeutic-plasma-exchange-shows-no-benefit-for-long-covid-treatment-in-phase-ii-trial 2025-02-24T19:32:42+00:00 hourly 0.9 https://trial.medpath.com/news/4a2322ac5d6fe37b/anti-pd1-precision-therapy-shows-promise-in-unresectable-stage-iii-nsclc-trial 2025-02-24T19:32:14+00:00 hourly 0.9 https://trial.medpath.com/news/7eb5642ecaa31bdf/hsd3b1-gene-variant-linked-to-poorer-survival-in-prostate-cancer-despite-intensive-therapy 2025-02-24T19:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/48d5f616cd18b062/physical-activity-significantly-improves-survival-outcomes-in-stage-iii-colon-cancer-patients 2025-02-24T19:31:46+00:00 hourly 0.9 https://trial.medpath.com/news/6c2b257ec4312fe1/ema-to-review-novel-topical-gene-therapy-beremagene-geperpavec-among-six-new-drug-applications 2025-02-24T19:31:31+00:00 hourly 0.9 https://trial.medpath.com/news/f5c9ac63363e91f2/onco-innovations-reports-favorable-safety-profile-for-novel-pknp-cancer-treatment-technology 2025-02-24T18:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2727c65320291eba/tempus-ai-reports-strong-growth-and-strategic-acquisition-of-ambry-genetics-in-q4-2024 2025-02-24T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/252fdeb05c0d401c/j-j-files-lawsuit-against-samsung-bioepis-over-stelara-biosimilar-contract-dispute 2025-02-24T17:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/6b536197e1c59fba/fda-clears-ind-for-ltz-301-a-novel-myeloid-engager-therapy-for-b-cell-lymphoma 2025-02-24T17:32:12+00:00 hourly 0.9 https://trial.medpath.com/news/8ffaabaa30efd666/first-patient-dosed-in-novel-riptac-cancer-therapy-trial-for-advanced-prostate-cancer 2025-02-24T17:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/1758f3382bc04603/summit-therapeutics-partners-with-pfizer-to-evaluate-novel-cancer-drug-combination-amid-financial-losses 2025-02-24T17:31:25+00:00 hourly 0.9 https://trial.medpath.com/news/5e39c8664f3dd89c/versamune-r-hpv-shows-promising-ctdna-clearance-and-survival-rates-in-advanced-cervical-cancer-trial 2025-02-24T16:34:37+00:00 hourly 0.9 https://trial.medpath.com/news/44fb411e754c8233/azitra-advances-clinical-programs-for-netherton-syndrome-and-egfr-inhibitor-associated-rash 2025-02-24T16:34:18+00:00 hourly 0.9 https://trial.medpath.com/news/28377b30f336a294/pepgen-reports-promising-splicing-correction-results-in-dm1-clinical-trial 2025-02-24T16:33:57+00:00 hourly 0.9 https://trial.medpath.com/news/a201c898621c671b/fda-grants-fast-track-designation-to-cbp-101-for-recurrent-endometrial-cancer-treatment 2025-02-24T16:33:35+00:00 hourly 0.9 https://trial.medpath.com/news/45c1dd901f9c75f9/fda-grants-orphan-drug-exclusivity-to-lumryz-for-narcolepsy-treatment-marking-first-once-nightly-oxybate-therapy 2025-02-24T16:33:17+00:00 hourly 0.9 https://trial.medpath.com/news/81f4433843c449f0/ataciguat-shows-promise-in-slowing-aortic-valve-stenosis-progression-mayo-clinic-study-reveals 2025-02-24T16:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/ae4f685c61d07f12/sonia-trial-reveals-optimal-timing-for-cdk4-6-inhibitors-in-advanced-breast-cancer-treatment 2025-02-24T16:32:18+00:00 hourly 0.9 https://trial.medpath.com/news/f0d9954bcc324cd7/co-diagnostics-withdraws-covid-19-test-fda-application-plans-enhanced-version-submission 2025-02-24T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/60a12e62e8d8ea8a/fda-sets-pdufa-date-for-glaukos-ilink-epi-on-for-non-surgical-keratoconus-treatment 2025-02-24T15:01:21+00:00 hourly 0.9 https://trial.medpath.com/news/62fef3a1fe826bd7/personalized-cancer-vaccines-show-promise-in-clinical-trials-marking-new-era-in-immunotherapy 2025-02-24T14:52:19+00:00 hourly 0.9 https://trial.medpath.com/news/b3846f3be9f09819/meiragtx-s-gene-therapy-shows-promising-visual-benefits-in-children-with-rare-genetic-blindness 2025-02-24T14:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/c84d43982c4d2c33/alpha-tau-secures-mdsap-certification-for-alpha-dart-cancer-therapy-manufacturing-facility 2025-02-24T13:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/6a8c14b64a371077/rxc008-shows-promise-as-first-in-class-treatment-for-fibrostenotic-crohn-s-disease-in-phase-1-trial 2025-02-24T13:34:21+00:00 hourly 0.9 https://trial.medpath.com/news/5102f34f8b3903af/an2-therapeutics-shifts-phase-3-mac-lung-disease-trial-to-quality-of-life-endpoint 2025-02-24T13:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/0d97273ba912f175/fda-grants-rmat-designation-to-novel-cell-therapy-for-dry-amd-treatment 2025-02-24T13:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/3b9af0d91fcb6be8/healx-initiates-phase-2-trial-of-ai-discovered-hlx-1502-for-neurofibromatosis-type-1-treatment 2025-02-24T13:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/c9ad8d39447cab55/summit-and-pfizer-partner-to-evaluate-novel-cancer-therapy-combinations-with-ivonescimab 2025-02-24T13:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/7a9df969fe31db76/nektar-and-trialnet-partner-to-test-novel-t-cell-therapy-rezpegaldesleukin-in-early-stage-type-1-diabetes 2025-02-24T13:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/32b33fdd9ee0d83a/gylden-pharma-advances-t-cell-priming-platform-with-multiple-clinical-trials-for-infectious-diseases-in-2025 2025-02-24T13:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/066afa168f772e02/lutetium-177-psma-617-shows-promise-in-advanced-prostate-cancer-treatment 2025-02-24T13:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/4cb9c7bf2aafc65e/xeris-biopharma-appoints-dr-anh-nguyen-as-chief-medical-officer-to-lead-product-development-strategy 2025-02-24T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/93f51afd8998e897/familiescn2a-and-cellectricon-join-forces-to-advance-drug-development-for-autism-and-epilepsy-linked-scn2a-gene 2025-02-24T12:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/951c2af48cd15c0e/ucb-launches-comprehensive-bimzelx-navigate-program-to-enhance-patient-access-and-support 2025-02-24T11:54:43+00:00 hourly 0.9 https://trial.medpath.com/news/01fcca7148090f6e/berkshire-biomedical-launches-equity-crowdfunding-for-revolutionary-copatm-medication-delivery-system 2025-02-24T11:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/ec9a27525fd5ff56/ema-approves-new-pre-filled-pen-option-for-takhzyro-in-hereditary-angioedema-treatment 2025-02-24T10:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/44499b04085ac043/ngm-bio-initiates-phase-2-trial-of-ngm120-for-hyperemesis-gravidarum-treatment 2025-02-24T10:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/39e2884a7f711a73/first-patient-enrolled-in-phase-ib-ii-trial-of-tasquinimod-for-treatment-resistant-myelofibrosis 2025-02-24T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2882f6d5e28be5d3/former-fda-drug-evaluation-director-patrizia-cavazzoni-appointed-as-pfizer-s-chief-medical-officer 2025-02-24T09:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/5772a89a36ae94cb/nih-funding-cuts-threaten-cancer-research-progress-and-early-career-scientists 2025-02-24T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/091017beab9bba1c/swiss-rockets-nasal-covid-19-vaccine-selected-for-niaid-project-nextgen-advances-cancer-therapeutics-pipeline 2025-02-24T07:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/3b544e7d82c937e5/pioneering-spinal-stimulation-therapy-enables-paralyzed-patient-to-walk-again-in-uk-trial 2025-02-24T07:32:55+00:00 hourly 0.9 https://trial.medpath.com/news/218f8241645ac6db/new-zealand-expands-groundbreaking-car-t-cell-therapy-trial-for-blood-cancer-patients 2025-02-24T07:32:41+00:00 hourly 0.9 https://trial.medpath.com/news/8d66a303a651a609/rna-editing-breakthroughs-show-clinical-promise-with-wave-life-sciences-leading-first-human-results 2025-02-24T07:32:20+00:00 hourly 0.9 https://trial.medpath.com/news/2a19ef02401b6c1b/fda-grants-emergency-authorization-for-20-minute-at-home-molecular-covid-flu-test 2025-02-24T07:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/f2f69cafb9cea2cc/braf-inhibitors-show-promise-in-treatment-of-relapsed-refractory-hairy-cell-leukemia 2025-02-24T06:52:10+00:00 hourly 0.9 https://trial.medpath.com/news/9c329fdb19483885/sandoz-launches-pyzchiva-a-new-ustekinumab-biosimilar-expanding-access-to-critical-autoimmune-treatment-in-us 2025-02-24T06:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/2c2e0a38e12f0d23/tandem-stem-cell-transplant-study-reveals-critical-complications-in-high-risk-neuroblastoma-treatment 2025-02-24T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/696dd4ce0d1a2c97/dana-farber-launches-innovative-pa-oncology-fellowship-to-address-growing-cancer-care-demands 2025-02-24T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9aa0369b5ac109b3/agenus-to-present-new-data-on-bot-bal-combination-therapy-at-aacr-io-meeting 2025-02-24T05:31:43+00:00 hourly 0.9 https://trial.medpath.com/news/012c6ff7cb35ead7/biocryst-s-orladeyo-demonstrates-safety-and-efficacy-in-pediatric-hereditary-angioedema-trial 2025-02-24T05:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/dc9fb0abe6eed2f5/immunovant-s-batoclimab-shows-promise-in-phase-3-myasthenia-gravis-trial-analysts-maintain-strong-buy-rating 2025-02-24T04:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/ccbda43014550378/memphasys-achieves-critical-milestone-in-felixtm-system-clinical-trial-for-advanced-sperm-selection 2025-02-24T04:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/5d75a5163bfddfc4/labcorp-expands-precision-oncology-portfolio-with-advanced-liquid-biopsy-and-mrd-testing-solutions 2025-02-24T04:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/0121d869b0f64493/long-term-study-reveals-similar-outcomes-for-acs-patients-with-and-without-traditional-risk-factors 2025-02-24T04:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/67b9ed927ef64d46/boehringer-ingelheim-introduces-novel-trivalent-vaccine-combining-h5-avian-flu-protection-with-core-poultry-immunizations 2025-02-24T04:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/7f690da6b6547cde/harvard-licensed-antibiotic-platform-launches-as-kinvard-bio-to-combat-drug-resistant-infections 2025-02-24T02:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/cda63ade821c2fba/better-choice-company-advances-acquisition-of-srx-health-solutions-following-unanimous-shareholder-approval 2025-02-24T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0607acd63d5b08a6/labconnect-and-australian-clinical-labs-form-strategic-alliance-to-expand-clinical-trial-services-in-asia-pacific 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aee91caa94b1ca0f/abbvie-s-abbv-706-receives-fda-orphan-drug-designation-for-small-cell-lung-cancer-treatment 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e7ca3c03aa5e2ed0/mgi-tech-and-oncoclinicas-co-partner-to-advance-genomic-cancer-diagnostics-in-brazil 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4a58586e034daeb9/celularity-and-bluesphere-bio-partner-on-manufacturing-tcr-t-cell-therapies-for-leukemia-treatment 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9439eb10115b4f80/novel-t-cell-therapy-shows-promising-results-in-castration-resistant-prostate-cancer-treatment 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/25b022d3a5ed31d3/fda-issues-warning-letter-to-jagsonpal-pharmaceuticals-for-critical-api-manufacturing-violations 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0513198055e51aa6/uk-pharmaceutical-reshoring-building-resilient-supply-chains-amid-global-disruptions 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/798cb993deb28e44/uk-biotech-secures-eur72m-series-a-to-advance-novel-gene-therapy-for-geographic-atrophy 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3a8c74b35e132a08/eisai-launches-novel-insurance-coverage-to-support-leqembi-access-in-japan 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8cc5185271e20afa/glp-1-diabetes-drugs-show-promising-potential-for-mental-health-treatment 2025-02-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1a00235989e282fa/telomir-pharmaceuticals-develops-novel-silver-ii-antimicrobial-to-combat-drug-resistant-infections 2025-02-23T23:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/aa29dfe741f4d9b2/final-ariel4-trial-results-show-limited-benefit-of-rucaparib-in-brca-ovarian-cancer 2025-02-23T22:31:33+00:00 hourly 0.9 https://trial.medpath.com/news/867ca32a61a809ed/uh-cancer-center-and-queen-s-health-systems-unite-to-launch-hawaii-s-first-on-campus-cancer-clinic 2025-02-23T22:31:16+00:00 hourly 0.9 https://trial.medpath.com/news/de7c176e4110197f/phase-1-trial-validates-fedratinib-s-safety-as-post-transplant-maintenance-therapy-for-mpn-patients 2025-02-23T20:31:20+00:00 hourly 0.9 https://trial.medpath.com/news/a2af4427c4a505c8/wvu-pioneers-first-human-stroke-treatment-with-stryker-s-novel-broadway-catheter-system 2025-02-23T13:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/c5b05d3c67ba8151/fda-launches-landmark-clinical-trial-to-assess-kratom-s-addiction-potential 2025-02-23T13:31:17+00:00 hourly 0.9 https://trial.medpath.com/news/2e590f81520b3840/expanding-biologic-options-transform-treatment-landscape-for-psoriatic-arthritis 2025-02-23T12:00:43+00:00 hourly 0.9 https://trial.medpath.com/news/e6904b45001ee898/dm199-s-novel-mechanism-for-acute-stroke-treatment-detailed-in-stroke-journal-publication 2025-02-23T08:01:16+00:00 hourly 0.9 https://trial.medpath.com/news/854364ad06246c5b/shift-in-mash-diagnosis-study-shows-growing-preference-for-noninvasive-testing-over-liver-biopsy 2025-02-23T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e03701b91e26948f/nhs-approves-fenfluramine-for-children-with-lennox-gastaut-syndrome-offering-new-hope-for-severe-epilepsy-treatment 2025-02-23T01:31:17+00:00 hourly 0.9 https://trial.medpath.com/news/499b04ee9a57c7ea/bluebird-bio-reports-promising-results-from-phase-1-2-gene-therapy-trial-plans-phase-3-study 2025-02-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f84c260e02e7a71c/obseva-seeks-fda-approval-for-novel-uterine-fibroid-treatment-with-flexible-hormone-therapy-options 2025-02-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5dce07ae91c3c664/roche-s-mysugr-pro-app-demonstrates-significant-reduction-in-diabetes-distress-in-clinical-trial 2025-02-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/01ecbbd44608ed5a/faron-s-traumakine-for-ards-receives-uk-s-promising-innovative-medicines-status 2025-02-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/492b102ddd27d7d6/histotripsy-shows-promise-for-treating-multiple-solid-tumors-beyond-liver-cancer 2025-02-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cd367c427af048ea/dr-reddy-s-laboratories-to-acquire-dutch-injectable-specialist-octoplus-for-eur27-39m 2025-02-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/851e2fd603cdd0ac/five-year-crown-trial-data-establishes-lorlatinib-as-first-line-standard-for-alk-nsclc 2025-02-22T22:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/5d9970d2df9f9680/novel-causal-forest-analysis-reveals-serum-potassium-s-role-in-vasopressin-treatment-response-for-septic-shock 2025-02-22T22:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/b521a7a5a861a8e4/dual-blood-pressure-medication-strategy-halves-arterial-events-in-veds-patients 2025-02-22T19:31:41+00:00 hourly 0.9 https://trial.medpath.com/news/5db1c66694f40c4f/tezepelumab-shows-remarkable-92-reduction-in-nasal-polyp-surgery-need-in-phase-3-trial 2025-02-22T19:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/2573cec1bc4b926d/shattuck-labs-sl-325-demonstrates-strong-safety-profile-in-pre-clinical-ibd-study 2025-02-22T16:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/6d28251495ed5577/bayer-to-showcase-advanced-radiology-portfolio-and-novel-contrast-agent-at-ecr-2025 2025-02-22T16:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/0a7dba3e2c1ebf94/ixinity-demonstrates-strong-safety-and-efficacy-profile-in-young-hemophilia-b-patients 2025-02-22T13:31:17+00:00 hourly 0.9 https://trial.medpath.com/news/6ab6f99e22d11d5c/omalizumab-shows-strong-real-world-success-one-year-after-food-allergy-approval 2025-02-22T10:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/b7c9cb64ae946d4e/novel-oral-a4b7-integrin-inhibitor-nsho-101-shows-promise-for-ibd-treatment-in-phase-1-data 2025-02-22T10:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/846d655a6c567bb6/dare-bioscience-and-theramex-partner-to-develop-novel-biodegradable-contraceptive-implant 2025-02-22T10:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/c29c7477386b21e5/fda-policy-change-expands-pharmacists-role-in-medication-abortion-access-bringing-new-challenges 2025-02-22T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/147fe1c6701163cc/persanta-advances-towards-ipo-with-dominari-securities-to-commercialize-early-cancer-detection-technology 2025-02-22T08:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/946d173960dd8fdc/protagonist-therapeutics-reports-strong-financial-growth-with-key-clinical-milestones-ahead-in-q1-2025 2025-02-22T07:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/f68410f67e6abcf6/gsk-s-relvar-ellipta-demonstrates-superior-asthma-control-in-landmark-real-world-study 2025-02-22T05:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/9b2b403756e999e6/bay-2927088-shows-promise-in-her2-mutant-nsclc-with-high-response-rates-in-phase-i-ii-trial 2025-02-22T01:31:58+00:00 hourly 0.9 https://trial.medpath.com/news/122780d25555a92a/merck-halts-final-phase-3-keytruda-trial-in-prostate-cancer-after-failed-interim-analysis 2025-02-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f729e35c9b271f9a/sensyne-health-expands-global-patient-data-access-through-strategic-phesi-partnership-and-ps27-5m-fundraising 2025-02-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3834db7fe3a4f4d1/fda-approves-phase-2-trial-of-revolutionary-bivacor-artificial-heart-device 2025-02-21T22:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/3b8db4a9f1dcfa0c/pancan-study-completes-enrollment-of-8800-participants-to-investigate-diabetes-pancreatic-cancer-link 2025-02-21T22:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/a01fdf81ff339013/uromems-smart-urinary-sphincter-implant-achieves-primary-endpoints-in-pioneering-female-sui-study 2025-02-21T22:31:47+00:00 hourly 0.9 https://trial.medpath.com/news/bb93a88b4b73d5c0/verastem-oncology-to-present-new-lgsoc-treatment-data-at-sgo-2025-annual-meeting 2025-02-21T20:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/19ae89b287a76507/estrella-s-eb103-cell-therapy-shows-promising-safety-profile-in-nhl-trial-s-first-cohort 2025-02-21T19:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/9a0de21a0ad1d595/dsm-firmenich-s-solid-cbd-formulation-matches-epidiolex-s-bioavailability-in-clinical-study 2025-02-21T19:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/d21d96a3274c8b7d/fda-approves-first-treatment-for-cerebrotendinous-xanthomatosis-mirum-s-chenodiol-tablets 2025-02-21T19:32:14+00:00 hourly 0.9 https://trial.medpath.com/news/21e4f1750da61da3/novel-compounds-nr-and-coq10-show-promise-in-improving-metabolism-and-reducing-inflammation-in-ckd-patients 2025-02-21T19:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/8c430724b2586247/novel-digital-cognitive-training-shows-promise-for-coronary-heart-disease-patients-in-clinical-trial 2025-02-21T19:31:38+00:00 hourly 0.9 https://trial.medpath.com/news/a2e0455ab235f507/novel-remote-ischemic-conditioning-protocol-shows-promise-in-protecting-heart-during-coronary-intervention 2025-02-21T19:31:16+00:00 hourly 0.9 https://trial.medpath.com/news/22e3657488c2530b/groundbreaking-car-t-cell-trial-at-ben-taub-hospital-shows-promise-in-multiple-myeloma-treatment 2025-02-21T18:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/e97da0057a38fe78/lupin-s-somerset-facility-receives-fda-establishment-inspection-report-confirming-compliance 2025-02-21T17:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/997cd9e13d1392a4/sera-prognostics-to-present-at-td-cowen-conference-and-report-q1-2025-results-in-may 2025-02-21T17:43:04+00:00 hourly 0.9 https://trial.medpath.com/news/3a0eb901701a905c/kalvista-to-present-sebetralstat-data-at-major-medical-conferences-as-fda-review-continues 2025-02-21T17:40:31+00:00 hourly 0.9 https://trial.medpath.com/news/36b0f74cacd18c30/phoenix-molecular-designs-initiates-phase-2-trial-of-pmd-026-combination-therapy-for-advanced-breast-cancer 2025-02-21T16:34:25+00:00 hourly 0.9 https://trial.medpath.com/news/241e2408427ce20c/intensive-blood-pressure-control-shows-net-benefits-for-seniors-in-sprint-trial-analysis 2025-02-21T16:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/d686aa1254898dde/abivax-announces-kol-webcast-to-discuss-obefazimod-phase-3-trial-in-ulcerative-colitis 2025-02-21T16:33:59+00:00 hourly 0.9 https://trial.medpath.com/news/bb9e247cb02eea72/breakthrough-gene-therapy-restores-vision-in-children-with-rare-genetic-blindness 2025-02-21T16:33:38+00:00 hourly 0.9 https://trial.medpath.com/news/99747e01352b684e/unmc-researcher-to-present-groundbreaking-icu-care-bundle-implementation-study-at-nih 2025-02-21T16:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/e8b091d779e33104/novel-ctdna-assay-shows-high-predictive-value-for-breast-cancer-recurrence-during-neoadjuvant-therapy 2025-02-21T16:31:25+00:00 hourly 0.9 https://trial.medpath.com/news/3f11df61b7685d88/boehringer-ingelheim-launches-pioneering-gene-therapy-trial-for-cystic-fibrosis-treatment 2025-02-21T14:01:26+00:00 hourly 0.9 https://trial.medpath.com/news/db90ac2db4963261/head-to-head-study-shows-bimekizumab-outperforms-brodalumab-in-psoriasis-treatment 2025-02-21T13:46:37+00:00 hourly 0.9 https://trial.medpath.com/news/f80018a5cb27ed53/seikagaku-launches-phase-iii-trials-for-single-injection-osteoarthritis-treatment-in-japan 2025-02-21T13:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/76715af4b1507ae0/ananda-pharma-achieves-gmp-manufacturing-milestone-for-mrx1-pain-treatment-program 2025-02-21T13:32:06+00:00 hourly 0.9 https://trial.medpath.com/news/614bf1bfb9be2676/novel-antifungal-drug-fosmanogepix-enters-clinical-trials-at-westmead-hospital-for-drug-resistant-infections 2025-02-21T13:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/a21c71143fcfb1c4/novel-hafnium-based-treatment-trial-launches-for-cisplatin-ineligible-head-and-neck-cancer-patients 2025-02-21T13:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/01487b4902ae9eeb/blood-pressure-drug-amlodipine-shows-promise-as-novel-adhd-treatment-in-preclinical-study 2025-02-21T12:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/c96564b72cacfd8d/nhs-trials-comedy-on-prescription-as-novel-alternative-to-antidepressants 2025-02-21T11:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/e13fc231e9bc435c/bantam-pharmaceutical-initiates-phase-1-trial-of-novel-mitochondrial-targeting-cancer-drug-at-md-anderson 2025-02-21T10:33:18+00:00 hourly 0.9 https://trial.medpath.com/news/835a64f6dd3334ab/lanifibranor-phase-1-trial-launches-in-japan-for-mash-treatment-development 2025-02-21T10:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/3435d4dafbf82bba/bluebird-bio-goes-private-in-29m-deal-with-carlyle-and-sk-capital-partners 2025-02-21T09:22:09+00:00 hourly 0.9 https://trial.medpath.com/news/b3f35b78b8d17173/fda-grants-breakthrough-status-to-hyperview-revolutionary-x-ray-system-promises-3000-better-breast-cancer-detection 2025-02-21T09:13:20+00:00 hourly 0.9 https://trial.medpath.com/news/c6e4be0545a2b6eb/cardiol-s-crd-38-shows-promise-in-heart-failure-treatment-with-novel-cannabidiol-approach 2025-02-21T08:26:22+00:00 hourly 0.9 https://trial.medpath.com/news/a1307956cde52bca/fda-declares-end-to-ozempic-shortage-novo-nordisk-shares-surge-while-competitors-feel-impact 2025-02-21T08:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/3140c0f4a3d7c3c0/fda-declares-end-to-ozempic-and-wegovy-shortages-as-novo-nordisk-ramps-up-supply 2025-02-21T08:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/fe9aebadfa020e02/phoenix-molecular-advances-to-phase-ii-trial-testing-novel-breast-cancer-combination-therapy 2025-02-21T08:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/6c1321255126c939/prothena-s-birtamimab-shows-promise-in-phase-3-trial-for-al-amyloidosis-with-focus-on-high-risk-patients 2025-02-21T07:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/ebe47d93f67810a0/cerebrovascular-reactivity-emerges-as-key-biomarker-for-dementia-risk-and-cognitive-decline 2025-02-21T07:11:45+00:00 hourly 0.9 https://trial.medpath.com/news/e1002453b4a74c58/shionogi-s-antibiotic-fetroja-receives-marketing-approval-in-south-korea-for-drug-resistant-infections 2025-02-21T07:11:26+00:00 hourly 0.9 https://trial.medpath.com/news/bbb2a73d8bd7bb11/fda-grants-510-k-clearance-to-atreon-s-biocharge-matrix-for-rotator-cuff-repair 2025-02-21T06:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/2636f7f03b519dca/low-adoption-of-proven-neoadjuvant-chemotherapy-in-primary-urethral-cancer-raises-treatment-access-concerns 2025-02-21T06:55:24+00:00 hourly 0.9 https://trial.medpath.com/news/97ea073c7991c772/stanford-expert-highlights-evolution-of-sma-assessment-tools-and-treatment-outcomes-across-age-groups 2025-02-21T06:48:07+00:00 hourly 0.9 https://trial.medpath.com/news/71cf7c52b537c9f1/cns-drug-development-faces-rising-trial-failures-despite-innovation-surge 2025-02-21T04:02:15+00:00 hourly 0.9 https://trial.medpath.com/news/a09ba4ab8de4b201/pfizer-discontinues-beqvez-gene-therapy-for-hemophilia-b-amid-low-market-demand 2025-02-21T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a03ff33b501dfe55/nevisense-ai-tool-significantly-improves-melanoma-biopsy-decisions-in-us-and-german-study 2025-02-21T02:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/091f4c2160852fef/symrise-partners-with-hbc-to-expand-marine-based-health-ingredients-portfolio 2025-02-21T02:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/4dc4e0c66699a167/astrazeneca-acquires-fibrogen-china-for-160-million-strengthening-roxadustat-position 2025-02-21T02:01:21+00:00 hourly 0.9 https://trial.medpath.com/news/bb0d187472066bbc/celestial-and-cosmic-312-trials-shape-future-of-hcc-treatment-landscape 2025-02-21T01:31:25+00:00 hourly 0.9 https://trial.medpath.com/news/d37388e16950b9cf/european-trial-launches-smart-screening-strategy-to-combat-rising-prostate-cancer-cases 2025-02-21T01:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/076e87bf3da2b177/data-management-challenges-threaten-to-slow-precision-medicine-progress 2025-02-21T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/88a53c86c2c409a9/onco-innovations-expands-market-presence-with-new-otcqb-listing-in-united-states 2025-02-21T00:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/100aa5ca7838d866/novartis-faces-scrutiny-over-1m-stock-sale-amid-zolgensma-data-manipulation-investigation 2025-02-20T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/4aba1a1cb00294f6/patient-reported-outcomes-and-real-world-data-reshape-treatment-landscape-in-cll-and-mcl 2025-02-20T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/1b0f8e160c69ef3b/brukinsa-demonstrates-superior-safety-profile-compared-to-imbruvica-in-cll-treatment-study 2025-02-20T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/89e1fa9eee333d62/roche-to-challenge-illumina-s-dominance-with-novel-sequencing-technology-launch-in-2024 2025-02-20T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/0c14ebd3b9e4fc95/study-reveals-link-between-achr-antibody-levels-and-myasthenia-gravis-treatment-response 2025-02-20T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/85a6dd707c14fd65/wave-life-sciences-achieves-historic-milestone-with-first-human-rna-editing-data-in-aatd-treatment 2025-02-20T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/372beb124ef9b426/revitalvision-launches-fda-cleared-digital-vision-training-platform-for-adult-amblyopia-treatment 2025-02-20T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/a23103ac5cb07512/fda-grants-historic-approval-to-biogen-s-qalsody-for-rare-genetic-form-of-als 2025-02-20T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/cd58a6c9b9a67811/luminal-a-dcis-shows-strong-response-to-letrozole-in-phase-ii-trial-genomic-study-reveals 2025-02-20T22:31:47+00:00 hourly 0.9 https://trial.medpath.com/news/a92550076aa4662b/paxlovid-shows-limited-benefit-in-vaccinated-older-adults-ucla-study-finds 2025-02-20T22:31:15+00:00 hourly 0.9 https://trial.medpath.com/news/519108d484c0ede0/dynavax-reports-strong-growth-with-heplisav-b-revenue-up-26-in-2024-advances-pipeline-programs 2025-02-20T20:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/270e0432c49a0460/roche-revolutionizes-genomic-sequencing-with-novel-sequencing-by-expansion-technology 2025-02-20T19:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/bae543fe420fc43e/neurona-s-nrtx-1001-cell-therapy-advances-to-phase-3-trial-for-drug-resistant-epilepsy 2025-02-20T19:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/be8c4222e88e36d6/fda-clears-zabalafin-hydrogel-ind-for-atopic-dermatitis-treatment-phase-2b-trials-to-begin-in-2025 2025-02-20T19:32:12+00:00 hourly 0.9 https://trial.medpath.com/news/d49c2a6076a0d880/novadip-s-novel-bone-graft-material-achieves-100-fracture-union-rate-in-phase-ib-iia-trial 2025-02-20T19:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/af65d74d835f6c46/alpha-stim-device-trial-successfully-adapts-to-covid-19-challenges-in-depression-treatment-study 2025-02-20T19:31:30+00:00 hourly 0.9 https://trial.medpath.com/news/b9871d160e1f600e/life-sciences-m-a-landscape-earnouts-dominate-deals-despite-low-success-rate-antitrust-scrutiny-intensifies 2025-02-20T18:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/22236409f80b5f19/boehringer-ingelheim-launches-first-in-class-inhaled-gene-therapy-trial-for-cystic-fibrosis 2025-02-20T17:01:48+00:00 hourly 0.9 https://trial.medpath.com/news/bc971a294bc1ef0d/spanish-energyco-trial-to-evaluate-energy-expenditure-in-school-commuting-methods-and-cycling-intervention 2025-02-20T16:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/09f441066e5c0225/eg-427-secures-eur27m-series-b-to-advance-novel-gene-therapy-for-spinal-cord-injury-related-bladder-dysfunction 2025-02-20T16:34:18+00:00 hourly 0.9 https://trial.medpath.com/news/b7f85f2b0a6e25cd/fda-grants-orphan-drug-designation-to-oxc-101-for-acute-myeloid-leukemia-treatment 2025-02-20T16:33:59+00:00 hourly 0.9 https://trial.medpath.com/news/e905c614c3b9c505/northsea-therapeutics-strengthens-executive-team-with-strategic-cfo-and-cmo-appointments 2025-02-20T16:33:39+00:00 hourly 0.9 https://trial.medpath.com/news/1fe2468ce1528852/study-reveals-major-discrepancies-in-cell-and-gene-therapy-trial-data-submitted-to-fda-and-ema 2025-02-20T16:33:18+00:00 hourly 0.9 https://trial.medpath.com/news/50adc7c6b49849b6/fda-approves-casgevy-world-s-first-crispr-based-treatment-for-sickle-cell-disease 2025-02-20T16:32:58+00:00 hourly 0.9 https://trial.medpath.com/news/0bcb543e64a3696d/immunic-s-imu-856-shows-promise-in-glp-1-elevation-and-weight-management-potential 2025-02-20T16:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/6e067bab84ad3b49/vaxxas-advances-novel-microneedle-patch-delivery-for-h7n9-bird-flu-vaccine-in-phase-i-trial 2025-02-20T16:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/aa22fd2cdebf2106/curasen-launches-phase-1-trial-of-curaax-for-neurogenic-orthostatic-hypotension-and-cognitive-impairment 2025-02-20T16:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/15ab10e93e03dfd9/peer-led-adhd-education-program-shows-promise-in-pilot-trial-for-newly-diagnosed-adults 2025-02-20T16:31:47+00:00 hourly 0.9 https://trial.medpath.com/news/7cc624f514a0b9de/tambiciclib-zanubrutinib-combo-shows-67-response-rate-in-relapsed-refractory-dlbcl-trial 2025-02-20T16:31:26+00:00 hourly 0.9 https://trial.medpath.com/news/1545e9fec7cecfe5/study-links-semaglutide-to-increased-risk-of-vision-threatening-eye-condition 2025-02-20T16:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/e5451dfc297d080d/fda-grants-breakthrough-therapy-status-to-skinte-for-diabetic-foot-ulcers 2025-02-20T15:01:14+00:00 hourly 0.9 https://trial.medpath.com/news/f13ab7fe72470f47/supernus-depression-drug-spn-820-fails-to-meet-primary-endpoint-in-phase-iib-trial 2025-02-20T14:31:50+00:00 hourly 0.9 https://trial.medpath.com/news/4e94fe05840f4a31/fda-grants-fast-track-status-to-brtx-100-for-chronic-lumbar-disc-disease-treatment 2025-02-20T14:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/1c6bb6e211b24372/personalized-mrna-vaccines-show-promise-in-early-phase-pancreatic-cancer-trial 2025-02-20T14:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/b93d224ab6d199f1/stifel-raises-price-target-on-trevi-therapeutics-as-haduvio-shows-promise-for-chronic-cough-treatment 2025-02-20T14:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/cbe2de82ff796ecb/study-shows-stable-ovarian-cancer-remission-rates-despite-covid-19-pandemic-disruptions 2025-02-20T14:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/b242051d26394f40/first-european-patient-enrolled-in-aaa-shape-pivotal-trial-testing-novel-aneurysm-treatment 2025-02-20T14:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/489282697110d3e0/seralutinib-shows-sustained-benefits-in-pah-responders-over-72-week-treatment-period 2025-02-20T13:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/b895d4995b68f49e/hemlibra-shows-significant-improvement-in-joint-pain-for-hemophilia-a-patients-in-78-week-study 2025-02-20T13:32:27+00:00 hourly 0.9 https://trial.medpath.com/news/41d31a58f860e8bd/nhs-approves-breakthrough-car-t-cell-therapy-liso-cel-for-advanced-lymphoma-patients 2025-02-20T13:32:12+00:00 hourly 0.9 https://trial.medpath.com/news/1d27126fef29242b/breakthrough-combined-drug-therapy-shows-near-complete-elimination-of-liver-cancer-in-study 2025-02-20T13:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/5b33882561cdc0e7/rapid-weight-loss-in-retatrutide-trial-raises-safety-concerns-despite-efficacy 2025-02-20T13:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/ff872b90c3025068/cleveland-clinic-brain-study-reveals-surprising-neurological-health-patterns-after-3-years 2025-02-20T13:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/e9767afe6d928011/eli-lilly-expands-beyond-glp-1-success-targets-neurological-disease-breakthroughs 2025-02-20T12:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/8206ae5cfa45417b/caredx-s-alloseq-cfdna-test-shows-strong-performance-in-large-european-kidney-transplant-study 2025-02-20T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/c50c5ba5e1af4320/trump-pressures-pharma-giants-reshore-manufacturing-or-face-tariffs 2025-02-20T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/84d8f50f4c816419/fda-grants-orphan-drug-designation-to-sanofi-s-rilzabrutinib-for-autoimmune-hemolytic-anemia 2025-02-20T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/7fd1bd08d471b041/cereno-scientific-advances-cs1-development-program-with-fda-type-c-meeting-request-for-pah-treatment 2025-02-20T10:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/11a62a5fb555bec2/formycon-s-ustekinumab-biosimilar-fyb202-shows-comparable-efficacy-to-stelara-r-in-clinical-studies 2025-02-20T10:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/e5d0013cca8ad9a6/ema-validates-aspaveli-r-extension-application-for-rare-kidney-diseases-c3g-and-ic-mpgn 2025-02-20T10:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/1962f0594460f04c/air-force-and-spark-biomedical-launch-trial-to-combat-motion-sickness-using-neurostimulation-technology 2025-02-20T09:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/927debde26b8fa19/rheumatoid-arthritis-market-set-to-reach-34-7-billion-by-2035-driven-by-novel-therapies-and-rising-obesity-rates 2025-02-20T09:18:36+00:00 hourly 0.9 https://trial.medpath.com/news/4e54ce556fa92d4a/lucid-diagnostics-expands-esoguard-access-through-concierge-medicine-and-secures-first-commercial-insurance-coverage 2025-02-20T08:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/b2419a1ad02e6efa/urgent-need-for-pediatric-specific-rare-disease-treatments-as-30-die-before-age-five 2025-02-20T08:27:53+00:00 hourly 0.9 https://trial.medpath.com/news/45bd239d3604e583/surgibox-secures-us-patents-for-portable-sterile-surgery-technology 2025-02-20T08:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/cea1759510d3078f/novel-oxysterol-based-antibiotics-show-promise-against-drug-resistant-pathogens 2025-02-20T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/89d9a7d06a64adbe/anti-il23p19-therapies-transform-ibd-treatment-landscape-ahead-of-ecco-2025 2025-02-20T07:54:14+00:00 hourly 0.9 https://trial.medpath.com/news/3ae2c120b3599eaa/cognition-therapeutics-develops-enhanced-manufacturing-process-for-alzheimer-s-drug-candidate-zervimesine 2025-02-20T07:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/a044e2885b601a50/harbour-biomed-forges-strategic-ai-partnership-with-insilico-medicine-for-antibody-discovery 2025-02-20T07:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/70fa1d6285d4ab73/ema-and-fda-align-on-phase-iii-program-for-irlab-s-mesdopetam-in-parkinson-s-disease 2025-02-20T07:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/f83563918d49af0e/digital-home-based-copd-care-program-shows-61-reduction-in-hospital-readmissions 2025-02-20T07:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/253ff4fcf7c6bed7/mainz-biomed-partners-with-swiss-lab-to-launch-novel-colorectal-cancer-screening-test 2025-02-20T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/38d119d969261b27/siemens-to-raise-eur1-4-billion-through-strategic-healthineers-stake-sale 2025-02-20T07:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/e40cd296d2275403/fda-grants-safe-to-proceed-status-for-britecyte-s-novel-osteoarthritis-treatment 2025-02-20T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8e5de436a7dba64a/novo-nordisk-s-amycretin-shows-promising-results-in-early-stage-clinical-trial 2025-02-20T05:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/185abd49ad4cb581/novel-immunotherapy-combinations-show-promise-in-advanced-thymic-cancers 2025-02-20T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f265f8f516d074a6/managing-adverse-events-in-dlbcl-targeted-therapies-key-considerations-for-clinicians 2025-02-20T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f39243ba3b563140/fda-layoffs-threaten-drug-safety-and-innovation-experts-warn-of-widespread-impact 2025-02-20T04:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/03f8fa169c6b227a/celltrion-s-phase-3-study-validates-yuflyma-s-interchangeability-with-humira-for-psoriasis-treatment 2025-02-20T04:31:38+00:00 hourly 0.9 https://trial.medpath.com/news/f334b0e9466d6c25/cabozantinib-nivolumab-ipilimumab-combination-for-advanced-rcc-shows-sustained-benefits-with-critical-safety-considerations 2025-02-20T04:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/ca0e21fd4675f70f/global-pharma-launch-trends-2024-apac-markets-gain-ground-as-innovation-hubs 2025-02-20T04:13:09+00:00 hourly 0.9 https://trial.medpath.com/news/43676a665d94dd36/cancer-mortality-rates-among-black-americans-show-decline-but-significant-disparities-persist 2025-02-20T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bc59ab529aa71f85/treatment-com-ai-acquires-rocket-doctor-to-enhance-ai-powered-healthcare-platform 2025-02-20T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f1da7077172dafa4/sanofi-divests-50-stake-in-consumer-health-unit-supernus-depression-drug-falls-short-in-trial 2025-02-20T01:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/8366b025afa419e1/nih-study-evaluates-text-messaging-strategies-to-improve-cardiovascular-care-management 2025-02-20T01:31:17+00:00 hourly 0.9 https://trial.medpath.com/news/194f1d5349aa2487/breakthrough-therapy-designations-driving-pharmaceutical-market-to-reach-287-5-billion-by-2029 2025-02-20T01:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/516689c9d9b9395c/genetic-variants-influence-success-of-smoking-cessation-drug-varenicline-landmark-study-finds 2025-02-20T00:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/519c39e1e4703f62/pipeline-analysis-reveals-85-drugs-in-development-for-metastatic-prostate-cancer-treatment 2025-02-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/796de20b049a07d0/radiance-biopharma-secures-1-2-billion-licensing-deal-for-novel-ror-1-targeted-cancer-therapy 2025-02-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/83c8bf1802fc0f40/ezra-secures-fda-clearance-for-enhanced-full-body-mri-cancer-screening-technology 2025-02-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a4a72778dcf964b7/india-to-launch-multi-cancer-vaccine-for-women-targeting-ages-9-16 2025-02-19T23:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/3186511b23195d66/fda-grants-immunitybio-authorization-to-supply-recombinant-bcg-amid-tice-bcg-shortage 2025-02-19T23:01:34+00:00 hourly 0.9 https://trial.medpath.com/news/db0ea27fa9ef384a/astrazeneca-s-saphnelo-secures-eu-approval-for-systemic-lupus-erythematosus-treatment 2025-02-19T23:01:13+00:00 hourly 0.9 https://trial.medpath.com/news/8f919e349e859355/stem-cell-transplantation-shows-promise-as-myeloid-directed-cellular-therapy-for-refractory-crohn-s-disease 2025-02-19T22:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/14925557d9a575fb/fda-issues-refusal-to-file-for-pitolisant-in-idiopathic-hypersomnia-treatment 2025-02-19T22:31:33+00:00 hourly 0.9 https://trial.medpath.com/news/4fa2fe12adc19cc2/navtemadlin-shows-promise-for-glioblastoma-treatment-when-combined-with-chemotherapy 2025-02-19T22:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/25f35c3c4c2fb99f/clinical-trial-diversity-crisis-black-patients-severely-underrepresented-in-multiple-myeloma-studies 2025-02-19T20:31:17+00:00 hourly 0.9 https://trial.medpath.com/news/76f660422628155a/study-supports-safe-discontinuation-of-nivolumab-axitinib-therapy-in-responsive-metastatic-rcc-patients 2025-02-19T19:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/0669c9e8993e2dc5/amplify-trial-shows-promise-acalabrutinib-combinations-outperform-chemoimmunotherapy-in-cll-sll-treatment 2025-02-19T19:32:18+00:00 hourly 0.9 https://trial.medpath.com/news/55d2946117e3a9e7/ema-grants-prime-designation-to-pioneer-lassa-fever-vaccine-marking-milestone-in-tropical-disease-prevention 2025-02-19T19:32:02+00:00 hourly 0.9 https://trial.medpath.com/news/fa899c6252a26a5f/first-patient-dosed-in-peluntamig-combination-therapy-trial-for-small-cell-lung-cancer 2025-02-19T19:31:34+00:00 hourly 0.9 https://trial.medpath.com/news/2336644b8902fd12/ai-powered-trueblue-trial-launches-to-revolutionize-postnatal-depression-detection 2025-02-19T19:31:15+00:00 hourly 0.9 https://trial.medpath.com/news/af071ed9e6cf9549/quality-of-life-studies-reveal-urban-rural-disparities-in-bladder-cancer-and-adt-impact-in-prostate-cancer-treatment 2025-02-19T18:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2de97009216890d5/novel-tesla-mri-head-coil-to-advance-lithium-brain-imaging-in-multiple-phase-ii-psychiatric-trials 2025-02-19T16:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/a8afdc9e8172bd01/anifrolumab-shows-60-reduction-in-organ-damage-progression-in-lupus-patients 2025-02-19T16:34:24+00:00 hourly 0.9 https://trial.medpath.com/news/3b5e6697892ceb83/atezolizumab-shows-promise-following-chemoradiotherapy-in-advanced-esophageal-cancer 2025-02-19T16:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/27cf5b4d8464605f/landmark-checkmate-816-trial-nivolumab-chemotherapy-combo-shows-survival-benefit-in-resectable-lung-cancer 2025-02-19T16:33:27+00:00 hourly 0.9 https://trial.medpath.com/news/d5fe700bbfa27d32/biomerica-s-infoods-ibs-test-shows-significant-pain-reduction-in-clinical-trial-particularly-effective-for-ibs-c-and-ibs-m-patients 2025-02-19T16:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/ef26776c10698f4b/predictive-oncology-raises-545k-through-direct-stock-offering-to-advance-ai-driven-drug-discovery-platform 2025-02-19T14:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/4830b705d56aab4c/fda-grants-priority-review-to-boehringer-s-zongertinib-for-her2-mutant-advanced-lung-cancer 2025-02-19T13:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/26d6ccdafcaf2dbc/arcus-s-hif-2a-inhibitor-shows-promise-in-kidney-cancer-despite-gilead-s-exit 2025-02-19T13:32:12+00:00 hourly 0.9 https://trial.medpath.com/news/b48ca87d7d959018/nanoviricides-nv-387-shows-promise-against-multiple-viral-threats-following-successful-phase-i-trial 2025-02-19T13:31:47+00:00 hourly 0.9 https://trial.medpath.com/news/5ffb121370c69eda/fda-aligns-with-chemomab-on-single-phase-3-trial-path-for-novel-psc-treatment-nebokitug 2025-02-19T13:31:20+00:00 hourly 0.9 https://trial.medpath.com/news/b423c1848bc148cf/hemogenyx-secures-ps285000-funding-for-aml-car-t-trial-through-convertible-notes 2025-02-19T13:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/cc27fd8193b0ddff/novel-egfr-inhibitors-and-early-detection-dr-geoff-oxnard-bridges-clinical-practice-and-drug-development 2025-02-19T13:00:41+00:00 hourly 0.9 https://trial.medpath.com/news/9b44dd63b3fe9dec/u-s-monoclonal-antibodies-market-projected-to-reach-284-9-billion-by-2034-growing-at-13-1-cagr 2025-02-19T12:08:49+00:00 hourly 0.9 https://trial.medpath.com/news/d94b8d0940308a11/light-ai-s-ai-algorithm-shows-96-5-accuracy-in-strep-throat-detection-via-smartphone-images 2025-02-19T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/20cecb2c59e2cf43/novel-toothpaste-based-immunotherapy-shows-promise-for-peanut-allergy-treatment-in-phase-1-trial 2025-02-19T11:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/1c1aae8046f8e299/rapid-on-site-car-t-cell-manufacturing-promises-cost-reduction-and-improved-patient-access 2025-02-19T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/670fd1a38d9d18c9/astrazeneca-and-lilly-form-500m-alliance-to-develop-novel-bace-inhibitor-for-alzheimer-s-disease 2025-02-19T10:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/5d3a199a0553bf06/pharmajet-s-needle-free-delivery-system-shows-promise-for-african-immunization-programs 2025-02-19T10:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/af9c0605ae07f224/jord-bioscience-raises-series-b-funding-to-advance-agricultural-microbial-solutions 2025-02-19T09:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/52cb06f590a57e2b/cmr-study-reveals-sex-specific-patterns-in-aortic-stenosis-women-show-better-survival-despite-similar-fibrosis-levels 2025-02-19T08:57:22+00:00 hourly 0.9 https://trial.medpath.com/news/eac9a15979b8b0d5/thetis-reports-positive-phase-1a-data-for-novel-ibd-drug-tp-317-demonstrating-blt1-target-engagement 2025-02-19T08:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/77e72f908f0220b7/fda-staff-cuts-impact-neuralink-trial-review-team-amid-brain-implant-oversight 2025-02-19T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/26f2801ad28a1b7b/essen-health-care-and-ownahealth-partner-to-revolutionize-diabetes-and-obesity-care-in-underserved-nyc-communities 2025-02-19T08:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/86de4f9b45a29fb2/alcon-launches-voyager-dslt-revolutionary-automated-laser-treatment-for-glaucoma 2025-02-19T08:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/f0afdf9d2a651e00/sonnet-biotherapeutics-unveils-novel-adc-platform-for-enhanced-cancer-drug-development 2025-02-19T07:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/eb707aaec2bb26a6/hpq-silicon-patents-novel-one-step-process-for-advanced-li-ion-battery-cathode-materials 2025-02-19T07:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/0f98353210ecc396/reverb-therapeutics-secures-12m-seed-funding-to-advance-novel-cytokine-targeting-platform 2025-02-19T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/96fc7d5fafa6d058/cumberland-s-vibativ-antibiotic-secures-chinese-nmpa-approval-for-severe-bacterial-infections 2025-02-19T06:32:36+00:00 hourly 0.9 https://trial.medpath.com/news/f58cc4f8946d4171/oncology-workforce-crisis-drives-push-for-enhanced-collaboration-and-value-based-care 2025-02-19T05:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/c5b33f582911f22e/outlook-therapeutics-ons-5010-bla-resubmission-progresses-amid-price-target-adjustment 2025-02-19T05:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/18abe91652f63517/predictive-oncology-secures-new-financing-through-at-market-direct-offering 2025-02-19T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2827fb1de0987a9f/amazon-and-msk-cancer-center-partner-to-accelerate-ai-driven-drug-discovery 2025-02-19T04:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/e0b9880a542bd44d/fda-grants-fast-track-status-to-neuren-s-novel-pitt-hopkins-syndrome-treatment 2025-02-19T04:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/c77617bb21b36b1d/septerna-halts-phase-1-trial-of-sep-786-for-hypoparathyroidism-due-to-safety-concerns 2025-02-19T04:31:33+00:00 hourly 0.9 https://trial.medpath.com/news/19bbb84c2953d403/scleroderma-autoantibody-types-influence-disease-progression-and-clinical-trial-outcomes 2025-02-19T04:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/2cbce8010059da66/better-choice-company-divests-halo-asia-operations-in-8-1-million-strategic-sale 2025-02-19T04:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/74fbd4d998d496fd/recursion-ceo-launches-250k-pre-seed-fund-to-counter-nih-funding-cuts 2025-02-19T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d7c89b3b88ea69d6/igc-pharma-advances-phase-2-alzheimer-s-trial-with-igc-ad1-reports-26-revenue-growth-in-q3-2025 2025-02-19T02:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/05b39411cf9a9131/imagion-biosystems-initiates-manufacturing-of-magsense-her2-imaging-agent-for-fda-application 2025-02-19T02:21:06+00:00 hourly 0.9 https://trial.medpath.com/news/f9da185685ce1a58/clinical-trial-complexity-drives-30-cost-increase-industry-faces-growing-challenges-in-drug-development 2025-02-19T02:14:36+00:00 hourly 0.9 https://trial.medpath.com/news/73fa41c48374b74c/novo-nordisk-files-830m-fraud-lawsuit-against-kbp-biosciences-over-failed-kidney-drug 2025-02-19T01:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/68fd63d039246222/rosuvastatin-trial-launches-to-enhance-rectal-cancer-treatment-response 2025-02-19T01:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/70b4301b9079134e/netramark-to-present-ai-powered-clinical-trial-analysis-tools-for-psychiatric-disorders-at-isctm-meeting 2025-02-19T01:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/a9facc2c5c3a2322/sanofi-completes-eur10-billion-sale-of-opella-to-cd-r-transforms-into-pure-play-biopharma 2025-02-19T01:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/779a3558d5b40ec8/tepezza-sales-surge-as-thyroid-eye-disease-treatment-market-expands-to-2-3-billion 2025-02-19T01:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/74be27c7889e8afa/fda-approves-vyjuvek-breakthrough-topical-gene-therapy-for-dystrophic-epidermolysis-bullosa 2025-02-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/024c8a69d6dbf942/finland-achieves-major-breakthrough-in-ms-treatment-diagnosis-time-cut-in-half-over-past-decade 2025-02-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/16195317c2551a1c/fda-rejects-astrazeneca-s-fasenra-for-nasal-polyp-treatment-additional-clinical-data-required 2025-02-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5dc6fff1f5e290ef/jak-inhibitors-show-promising-efficacy-in-alopecia-areata-treatment-according-to-meta-analysis 2025-02-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8b22c4ace475340d/novel-sponge-like-implant-and-nanoparticle-therapy-shows-promise-in-multiple-sclerosis-treatment 2025-02-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/272e5e998bb140de/ai-and-community-health-workers-unite-to-transform-clinical-trial-access-and-skin-cancer-care 2025-02-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/94ddc4c1d05a2863/epitopea-and-msd-partner-in-300m-deal-to-develop-novel-cancer-immunotherapies-using-junk-dna-antigens 2025-02-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/87316ab00a5ef238/pirtobrutinib-shows-superior-efficacy-in-btk-inhibitor-pretreated-cll-patients 2025-02-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/61e9bb2485bfa720/myriad-genetics-to-participate-in-major-healthcare-investor-conferences-in-may-june-2025 2025-02-18T22:54:17+00:00 hourly 0.9 https://trial.medpath.com/news/748e5145ef51880f/medicus-pharma-initiates-phase-2-study-with-fast-track-potential 2025-02-18T22:32:11+00:00 hourly 0.9 https://trial.medpath.com/news/a8b06eb901fd9924/protocol-amendment-expands-anixa-s-ovarian-cancer-car-t-trial-second-dosing-and-new-cancer-types-added 2025-02-18T22:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/49bd5fbd3f08e9a8/breakthrough-blood-test-for-early-ovarian-cancer-detection-enters-clinical-trials-in-australia 2025-02-18T22:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/526ef062c94af1eb/innocan-pharma-secures-indian-patent-for-novel-liposomal-cbd-pain-treatment-platform 2025-02-18T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/878c5a7fd320d5c3/purple-biotech-launches-phase-2-trial-of-nt219-for-drug-resistant-head-and-neck-cancer 2025-02-18T20:01:22+00:00 hourly 0.9 https://trial.medpath.com/news/bef596adc7fd3f78/b-braun-introduces-revolutionary-emergency-department-nerve-block-tray-to-reduce-opioid-use 2025-02-18T19:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/b3a166354f2286c8/real-world-study-validates-rituximab-lenalidomide-efficacy-in-indolent-non-hodgkin-lymphoma-treatment 2025-02-18T19:32:43+00:00 hourly 0.9 https://trial.medpath.com/news/159bacbe131cd474/voiant-s-imaging-endpoints-support-fda-approval-of-new-treatments-for-colorectal-cancer-and-glioma 2025-02-18T19:32:26+00:00 hourly 0.9 https://trial.medpath.com/news/d3874a7954213e72/medtronic-plans-fda-submission-for-hugo-surgical-robot-eyes-us-launch-in-fy2026 2025-02-18T19:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/392a6e79ee1fe67f/opus-genetics-advances-lca5-gene-therapy-program-with-first-pediatric-patient-dosing-and-promising-adult-data 2025-02-18T19:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/3e5dbf7882d6b53d/ucsd-to-evaluate-nexalin-s-halo-device-for-ptsd-and-brain-injury-treatment-in-independent-clinical-trial 2025-02-18T19:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/2e9baba3cfcc942f/life-spine-s-gruve-cervical-plating-system-receives-fda-clearance-for-spinal-surgery 2025-02-18T17:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/94bac28942a27237/northstrive-biosciences-seeks-fda-guidance-for-novel-muscle-preserving-obesity-treatment-el-22 2025-02-18T17:04:37+00:00 hourly 0.9 https://trial.medpath.com/news/0b85bfbd57022b4d/novel-at-home-type-1-diabetes-test-could-transform-pediatric-diagnosis-in-uk-nhs-study 2025-02-18T16:36:51+00:00 hourly 0.9 https://trial.medpath.com/news/0e2b4ed32d3fa21d/ventyx-s-vtx958-shows-promising-endoscopic-response-in-phase-2-crohn-s-disease-trial-despite-missing-primary-endpoint 2025-02-18T16:36:33+00:00 hourly 0.9 https://trial.medpath.com/news/84c494f31a21d47a/algotx-s-phase-2-cipn-trial-shows-promise-for-atx01-despite-placebo-effect-challenges 2025-02-18T16:36:15+00:00 hourly 0.9 https://trial.medpath.com/news/71a3e3d4599608ea/parazero-s-precision-airdrop-system-advances-to-phase-ii-defense-testing-for-critical-medical-supply-delivery 2025-02-18T16:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/a5085f5903a2c7a7/namodenoson-shows-promise-in-treating-decompensated-liver-cirrhosis-patient-s-remarkable-recovery-in-compassionate-use-program 2025-02-18T16:35:31+00:00 hourly 0.9 https://trial.medpath.com/news/f3a9d3f897b51da8/axsome-therapeutics-reports-strong-growth-with-88-revenue-increase-in-2024-advances-cns-pipeline 2025-02-18T16:35:10+00:00 hourly 0.9 https://trial.medpath.com/news/1eaf64986c38595e/fda-greenlights-bonus-biogroup-s-phase-iii-trial-for-novel-ards-treatment 2025-02-18T16:34:54+00:00 hourly 0.9 https://trial.medpath.com/news/349d19467fc8eb9b/tivumecirnon-keytruda-combination-shows-promise-in-ebv-positive-gastric-cancer-trial 2025-02-18T16:34:37+00:00 hourly 0.9 https://trial.medpath.com/news/cc488348c232bc13/tg-therapeutics-to-present-new-briumvi-data-in-multiple-sclerosis-at-actrims-2025-forum 2025-02-18T16:34:15+00:00 hourly 0.9 https://trial.medpath.com/news/a2ba88fe3540bb39/cabaletta-bio-s-rese-cel-shows-promising-results-in-multiple-autoimmune-diseases-achieving-drug-free-remission 2025-02-18T16:33:52+00:00 hourly 0.9 https://trial.medpath.com/news/1546d5a11a95be01/extracellular-vesicles-emerge-as-revolutionary-platform-for-large-scale-biomanufacturing-and-clinical-applications 2025-02-18T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4c11162e8a4c0dcc/predictive-oncology-s-ai-platform-accelerates-cancer-drug-discovery-outperforming-standard-treatment 2025-02-18T15:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/bcaf5bcbd6f6a664/children-s-minnesota-launches-groundbreaking-vaccine-trial-for-deadly-pediatric-brain-cancer 2025-02-18T14:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/adbd7272b59e5ba0/pillar-biosciences-and-hamilton-partner-to-automate-ngs-testing-with-advanced-liquid-handling-systems 2025-02-18T14:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/133fbb69a8fdc4b5/optyx-study-patients-and-physicians-prefer-oral-relugolix-over-injectable-adt-for-advanced-prostate-cancer 2025-02-18T14:02:01+00:00 hourly 0.9 https://trial.medpath.com/news/b5bb6e6c05df7b6f/study-reveals-gap-in-advanced-prostate-cancer-treatment-adoption-between-academic-and-community-physicians 2025-02-18T14:01:44+00:00 hourly 0.9 https://trial.medpath.com/news/dc728d8d79f8426b/fda-grants-second-breakthrough-therapy-designation-for-petosemtamab-in-head-and-neck-cancer 2025-02-18T14:01:13+00:00 hourly 0.9 https://trial.medpath.com/news/86e41e4628149262/fda-grants-priority-review-to-dupixent-for-bullous-pemphigoid-treatment 2025-02-18T13:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/0751cd4a40623373/mount-sinai-s-dr-vivek-reddy-to-lead-orchestra-biomed-s-backbeat-study-as-executive-chairman 2025-02-18T13:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/ddb3b4b787945ba1/precision-medicine-and-biomarker-driven-approaches-transform-sarcoma-treatment-landscape 2025-02-18T11:59:29+00:00 hourly 0.9 https://trial.medpath.com/news/fb27f29098da2c38/u-s-gene-therapy-market-projected-to-reach-22-23-billion-by-2034-growing-at-19-8-cagr 2025-02-18T11:45:09+00:00 hourly 0.9 https://trial.medpath.com/news/ca06286e84cbc4f4/preoperative-immunonutritional-status-emerges-as-critical-predictor-of-ovarian-cancer-outcomes-in-large-chinese-study 2025-02-18T11:00:22+00:00 hourly 0.9 https://trial.medpath.com/news/850ef1987f3344c2/fda-clears-navi-medical-s-groundbreaking-ecg-tip-location-system-for-neonatal-central-line-placement 2025-02-18T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2cb442d36fdfe717/shionogi-secures-japan-s-first-adhd-digital-therapeutic-approval-with-endeavorride 2025-02-18T10:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/2e02381b2f46398e/cdc-study-reveals-silent-spread-of-h5n1-bird-flu-among-veterinarians-as-new-strains-emerge 2025-02-18T10:25:17+00:00 hourly 0.9 https://trial.medpath.com/news/6d0772fc34e1e041/vaxxas-advances-revolutionary-needle-free-vaccine-patch-in-largest-hd-map-clinical-trial 2025-02-18T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/12ce49144aa7bf47/endovascular-engineering-secures-42m-series-b-to-advance-novel-pulmonary-embolism-treatment 2025-02-18T09:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/e92cd45da29b4780/patient-advocacy-groups-lead-fight-against-colorectal-cancer-care-disparities-takeda-study-reveals 2025-02-18T09:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/bf13a9cafa6b2b7b/aidoc-s-foundation-model-powered-ai-for-rib-fracture-detection-receives-fda-clearance 2025-02-18T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0a1795e433d8348b/syrenity-mental-health-app-shows-promise-in-reducing-depression-symptoms-in-indiana-university-study 2025-02-18T08:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/7dd64093a58c7f28/thykaminetm-shows-promising-anti-fibrotic-effects-through-significant-gene-expression-changes-in-preclinical-study 2025-02-18T08:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/e0e7fc1925c0b3ab/combination-immunotherapy-achieves-51-seven-year-survival-rate-in-advanced-melanoma-brain-metastases 2025-02-18T08:31:15+00:00 hourly 0.9 https://trial.medpath.com/news/e0bbadb369eb6262/allurion-to-study-combined-glp-1-and-gastric-balloon-therapy-for-enhanced-obesity-treatment 2025-02-18T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/06c72b95512c9850/celltrion-secures-eu-approval-for-denosumab-biosimilars-targeting-osteoporosis-and-cancer-complications 2025-02-18T07:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/1d24f90fe4fba5d5/plus-therapeutics-raises-5-7m-to-advance-novel-radiotherapy-for-leptomeningeal-metastases 2025-02-18T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/d2db29202ed56aa2/heartsense-uncovers-hidden-cardiovascular-disease-burden-in-underserved-communities 2025-02-18T07:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/232c5c8f668a5142/study-reveals-major-disparities-in-us-health-insurance-coverage-for-pharmacogenetic-testing 2025-02-18T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/87e650632798f127/bristol-myers-squibb-renews-commitment-to-single-cell-data-science-consortium-for-phase-2 2025-02-18T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/408527aacdebed6a/harper-health-partners-with-opendna-to-launch-ai-powered-genetic-screening-services 2025-02-18T05:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/e98e04d6c2cec723/phase-iii-trial-confirms-strong-immune-response-to-two-dose-meningococcal-vaccine-series-in-adolescents 2025-02-18T04:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/5260a10ec9abcc80/hanchorbio-s-hcb101-advances-in-clinical-trials-leading-novel-cd47-targeting-immunotherapy-pipeline 2025-02-18T04:31:31+00:00 hourly 0.9 https://trial.medpath.com/news/5c9b364b00e9dc61/fda-approves-ono-pharmaceutical-s-novel-therapy-for-tgct-expanding-treatment-options 2025-02-18T04:31:13+00:00 hourly 0.9 https://trial.medpath.com/news/22895b3c465db05d/galapagos-launches-15-year-hesperia-study-to-track-long-term-outcomes-of-car-t-therapies 2025-02-18T01:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/3f3666f28d8511ad/new-trials-challenge-thrombectomy-benefits-for-medium-and-distal-vessel-stroke 2025-02-18T01:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/edfe43eaa70dfd48/uk-life-sciences-sector-faces-manufacturing-gap-despite-research-excellence 2025-02-18T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/11f2c3a06ec1fa91/u-s-legislation-proposes-ai-systems-as-legal-drug-prescribers 2025-02-18T00:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/70b724e27215f95e/loqus23-therapeutics-names-industry-veteran-cyrus-mozayeni-as-board-chair-following-ps35m-series-a 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/40cdbf56fd37bce1/meta-analysis-reveals-statins-boost-effectiveness-of-cancer-immunotherapy 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/87ed1135b96156ec/uthealth-houston-pioneers-telerehabilitation-trial-for-underserved-stroke-patients-in-rio-grande-valley 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/e3f7bfa0adcb0c45/fda-tightens-requirements-for-china-developed-drugs-mandates-multi-regional-trials 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/08bbb3b5d94fc6dc/cambridge-cognition-advances-digital-assessment-tool-for-schizophrenia-related-cognitive-impairment 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/190d5d72c87932e2/novel-injectable-gallium-based-paste-shows-promise-for-revolutionary-bone-cancer-treatment 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/ce4fb2e54c689b2f/large-scale-study-confirms-sugammadex-s-safety-and-efficacy-in-myasthenia-gravis-patients-post-surgery 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/3f6e37a796c78650/biogen-secures-global-rights-to-novel-dravet-syndrome-treatment-in-550m-deal 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/4cb94a752c5c7ec6/novel-blood-test-breakthrough-promises-less-invasive-monitoring-for-childhood-cancer-treatment 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/a23d35b953bd854a/septerna-halts-phase-i-trial-of-hypoparathyroidism-drug-sep-786-due-to-safety-concerns 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/1efab32f885c9ed2/fda-approves-lilly-s-retevmo-as-first-targeted-therapy-for-ret-positive-lung-and-thyroid-cancers 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/a877193a1ea20aa9/fda-approves-takeda-s-exkivity-as-first-oral-therapy-for-egfr-exon20-nsclc 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/e9fed70409eaaa33/lisdexamfetamine-shows-variable-efficacy-in-binge-eating-disorder-treatment-rutgers-study-finds 2025-02-17T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/a67c181f24071275/novel-grass-pollen-immunotherapy-shows-superior-20-3-symptom-reduction-in-landmark-phase-3-trial 2025-02-17T22:32:46+00:00 hourly 0.9 https://trial.medpath.com/news/8685ba62b210d33c/novel-sod1-targeting-drug-qalsody-shows-unprecedented-improvement-in-genetic-als-patients 2025-02-17T22:32:27+00:00 hourly 0.9 https://trial.medpath.com/news/8ece82f47382f348/teriparatide-biosimilar-rgb-10-demonstrates-equivalent-efficacy-to-reference-drug-in-high-risk-osteoporosis-patients 2025-02-17T22:32:06+00:00 hourly 0.9 https://trial.medpath.com/news/335be197c59fb120/groundbreaking-18-year-remission-achieved-in-neuroblastoma-patient-following-car-t-cell-therapy 2025-02-17T22:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/355a6522dac104a1/novel-treatment-approaches-show-promise-in-brain-cancer-from-aerosolized-drugs-to-personalized-vaccines 2025-02-17T22:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/ba82752fee3f6c8a/fragile-x-syndrome-market-set-for-83-2m-growth-with-novel-therapeutic-approaches 2025-02-17T20:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/1a45ebadc8984d05/ai-powered-screening-doubles-enrollment-rate-in-heart-failure-clinical-trial 2025-02-17T19:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/a3396cccb06db281/fda-clears-first-direct-to-consumer-genetic-test-for-celiac-disease-risk 2025-02-17T18:21:24+00:00 hourly 0.9 https://trial.medpath.com/news/afe7fb273ac8a422/formycon-halts-phase-iii-trial-of-fyb206-following-fda-feedback-faces-market-challenges-for-biosimilars 2025-02-17T16:33:57+00:00 hourly 0.9 https://trial.medpath.com/news/7b3efdd095cdf1a9/innocare-s-bcl2-inhibitor-icp-248-combination-therapy-advances-to-phase-iii-trial-for-first-line-cll-sll-treatment-in-china 2025-02-17T16:33:35+00:00 hourly 0.9 https://trial.medpath.com/news/dac1a2b489c63629/vivistim-vns-therapy-shows-promising-real-world-outcomes-in-chronic-stroke-recovery 2025-02-17T16:33:13+00:00 hourly 0.9 https://trial.medpath.com/news/e8c0b0e6c648b1da/phase-3-terzo-trial-to-evaluate-duvelisib-in-rare-t-cell-lymphoma-following-promising-phase-2-results 2025-02-17T16:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/7f1d2ce2b07e67bf/istesso-s-leramistat-misses-primary-endpoint-in-phase-2b-rheumatoid-arthritis-trial-shows-promise-in-bone-protection 2025-02-17T16:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/eebc93c92051829a/swissmedic-and-swissethics-release-new-guidelines-for-decentralized-clinical-trials 2025-02-17T16:32:10+00:00 hourly 0.9 https://trial.medpath.com/news/c0dc209037ba8010/bladder-preserving-treatment-shows-promise-radiation-plus-dual-immunotherapy-achieves-93-complete-response-in-mibc 2025-02-17T16:31:49+00:00 hourly 0.9 https://trial.medpath.com/news/b825f4a8d17d16cc/tg-therapeutics-partners-with-maxcyte-to-advance-novel-car-t-cell-therapy-for-progressive-ms 2025-02-17T16:31:30+00:00 hourly 0.9 https://trial.medpath.com/news/e0e3c5c2589277fe/scholar-rock-s-myostatin-blocking-antibody-advances-to-fda-review-for-spinal-muscular-atrophy 2025-02-17T16:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/a6e19214b5b40093/icc-tribunal-rules-in-aop-health-s-favor-over-besremi-licensing-dispute-with-pharmaessentia 2025-02-17T14:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/ef5a3596249be9f4/psma-targeted-therapies-transform-prostate-cancer-treatment-landscape 2025-02-17T13:55:48+00:00 hourly 0.9 https://trial.medpath.com/news/25757772d67fb94d/leramistat-shows-promise-in-bone-protection-for-rheumatoid-arthritis-despite-missing-primary-endpoint 2025-02-17T13:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/10b512aaa17e86d0/in8bio-s-inb-100-shows-promising-phase-1-results-with-zero-relapses-in-high-risk-aml-patients 2025-02-17T13:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/bbd1e0023193726a/12-month-study-shows-promising-safety-and-efficacy-of-esmethadone-for-major-depression 2025-02-17T13:32:02+00:00 hourly 0.9 https://trial.medpath.com/news/2e35b875052fecbd/bambusa-therapeutics-secures-90m-series-a-to-advance-novel-bispecific-antibody-pipeline 2025-02-17T13:31:43+00:00 hourly 0.9 https://trial.medpath.com/news/e828f72b590468fe/guard-therapeutics-announces-sek-150m-rights-issue-to-advance-kidney-protection-drug-development 2025-02-17T13:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/8477dcf33ec3e2bd/study-reveals-significant-racial-and-ethnic-disparities-in-psoriatic-arthritis-care-and-research 2025-02-17T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4419abb82f0decb8/dsmb-endorses-safety-of-foresee-s-camcevi-in-pediatric-precocious-puberty-trial 2025-02-17T10:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/942086f9ddd9dcbb/glenmark-and-fdc-initiate-major-drug-recalls-in-us-market-over-quality-concerns 2025-02-17T09:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/6836cb0b7969cf0f/uk-mhra-approves-sobi-s-efanesoctocog-alfa-for-haemophilia-a-treatment 2025-02-17T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dbeacf62d1ca1e7d/higher-calcium-intake-associated-with-29-lower-colorectal-cancer-risk-in-large-nih-aarp-study 2025-02-17T08:29:23+00:00 hourly 0.9 https://trial.medpath.com/news/874d21fe87670d79/edx-medical-unveils-novel-multi-biomarker-test-for-enhanced-prostate-cancer-detection 2025-02-17T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/98271c6f37573103/fda-greenlights-phase-2-trial-of-tpx-115-cell-therapy-for-rotator-cuff-tears 2025-02-17T07:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/610e08ce2ab9e951/lunsumio-shows-durable-3-year-remission-in-follicular-lymphoma-setting-new-benchmark-for-bispecific-antibodies 2025-02-17T07:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/cbde44d8cf12445f/first-in-human-trial-launches-for-novel-extracellular-vesicle-therapy-in-crohn-s-fistulas 2025-02-17T07:31:16+00:00 hourly 0.9 https://trial.medpath.com/news/0e9b8a61dc1e936f/blue-light-cystoscopy-reveals-hidden-bladder-tumors-improves-cancer-staging-in-major-registry-study 2025-02-17T06:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/51febf9c39c478c5/leading-biotech-companies-to-convene-at-6th-cytokine-based-drug-development-summit-2025-in-boston 2025-02-17T06:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/9b321f463ae3e43f/aav-gene-therapy-market-projected-to-reach-107-2-billion-by-2035-growing-at-40-cagr 2025-02-17T06:27:29+00:00 hourly 0.9 https://trial.medpath.com/news/010b0672166ed257/five-year-data-shows-promise-for-immunotherapy-combinations-in-metastatic-nsclc-treatment 2025-02-17T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/052991d8aaaeb8da/cellistic-launches-immune-cloaked-ipsc-cell-lines-to-accelerate-cell-therapy-development 2025-02-17T05:49:42+00:00 hourly 0.9 https://trial.medpath.com/news/eaccdbdd9edff45f/texas-oncology-pioneers-solutions-for-financial-barriers-and-rural-clinical-trial-access 2025-02-17T05:42:45+00:00 hourly 0.9 https://trial.medpath.com/news/0ab6c5e103648471/treatment-sequencing-strategies-for-brca-mutated-early-stage-tnbc-balancing-parp-inhibition-and-immunotherapy 2025-02-17T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/61359d91e19999b3/fda-grants-second-fast-track-designation-to-alginomics-rz-001-for-hepatocellular-carcinoma-treatment 2025-02-17T04:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/5652af90011dc01b/tga-approves-wegovy-for-cardiovascular-disease-prevention-in-overweight-patients 2025-02-17T04:31:54+00:00 hourly 0.9 https://trial.medpath.com/news/8046afc7f42f5a92/cdk4-6-inhibitors-show-consistent-benefits-in-premenopausal-advanced-breast-cancer-patients-across-major-trials 2025-02-17T03:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/a556bf801c4363ba/novel-topical-acne-therapies-show-promising-results-in-clinical-trials 2025-02-17T01:32:06+00:00 hourly 0.9 https://trial.medpath.com/news/4b4ec641458ce765/fda-grants-second-fast-track-designation-to-innovent-s-ibi363-for-advanced-squamous-nsclc-treatment 2025-02-17T01:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/fe1dd05449a2d235/auckland-researchers-launch-clinical-trial-to-investigate-5fu-chemotherapy-cardiotoxicity 2025-02-17T01:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/6240e2e3326663e3/nx-taiwan-achieves-historic-medical-device-qms-certification-first-among-japanese-companies 2025-02-17T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a245935f3eb851ca/fda-clears-thermo-fisher-s-multiplex-test-for-simultaneous-detection-of-covid-19-flu-and-rsv 2025-02-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/98b122a2a8ad3cc7/ps1m-grant-awarded-to-develop-novel-bama-inhibitor-against-drug-resistant-bacteria 2025-02-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b5673420ad57a0e0/global-clinical-trials-in-renal-cell-carcinoma-show-critical-geographic-and-economic-disparities 2025-02-16T22:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/a676b451c841c164/novel-non-myeloablative-hsct-protocol-shows-promise-for-kidney-transplant-immune-tolerance 2025-02-16T22:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/3df0fda7fc21ba3b/navenibart-shows-promise-in-reducing-hereditary-angioedema-attacks-in-phase-1b-2-trial 2025-02-16T22:31:31+00:00 hourly 0.9 https://trial.medpath.com/news/49afb6fbdcc66072/chinese-cancer-drug-outperforms-merck-s-keytruda-in-landmark-lung-cancer-trial 2025-02-16T22:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/9022c647b3649528/access-trial-shows-promising-survival-rates-with-ptcy-gvhd-prophylaxis-in-hla-mismatched-transplants 2025-02-16T19:31:47+00:00 hourly 0.9 https://trial.medpath.com/news/3affb48fa7fd8f0f/orca-t-immunotherapy-shows-enhanced-t-cell-activation-pattern-in-hematologic-malignancies-study 2025-02-16T19:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/8761a32d540aeadf/lenvatinib-tislelizumab-combo-shows-promising-93-response-rate-in-rare-hereditary-kidney-cancer 2025-02-16T17:01:16+00:00 hourly 0.9 https://trial.medpath.com/news/ecde57d5b4611831/stanford-study-shows-success-in-training-healthcare-providers-on-plant-based-diet-counseling 2025-02-16T16:31:17+00:00 hourly 0.9 https://trial.medpath.com/news/f0f223f368f8b76a/high-dose-aflibercept-shows-superior-fluid-control-in-96-week-pulsar-trial-analysis-for-wet-amd 2025-02-16T13:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/ad74a06b87450406/fda-approves-samsung-bioepis-denosumab-biosimilars-for-bone-health-conditions 2025-02-16T13:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/02c57259c02a2ba0/wvu-leads-national-trial-of-novel-jellyfish-inspired-brain-aneurysm-device 2025-02-16T13:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/dbb94ed245c4eb6e/fda-approves-tarlatamab-as-first-dll3-targeted-therapy-for-small-cell-lung-cancer 2025-02-16T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/f38d183eb8fce3c2/five-novel-9-month-oral-regimens-show-promise-in-phase-3-trial-for-drug-resistant-tb 2025-02-16T04:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/3934fd354bd3834a/reverse-switch-from-infliximab-biosimilar-to-remicade-shows-sustained-efficacy-in-ibd-patients 2025-02-16T04:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/286ea7f8dcf59ab5/novel-oral-psoriasis-therapies-show-promise-tyk2-inhibitors-lead-breakthrough-advances 2025-02-16T04:31:16+00:00 hourly 0.9 https://trial.medpath.com/news/35047c9fa6506bf4/uk-regulator-scrutinizes-moderna-over-covid-19-vaccine-trial-recruitment-practices 2025-02-16T02:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/1144b3b842edcd09/novel-dual-receptor-car-t-cell-therapy-a2b694-enters-clinical-trial-for-pancreatic-cancer-treatment 2025-02-16T01:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/b53871f6136c8b78/cemiplimab-plus-chemotherapy-shows-promise-in-advanced-penile-cancer-epic-trial 2025-02-16T01:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/ccfb097aaa724930/avelumab-maintenance-shows-consistent-survival-benefits-in-advanced-urothelial-cancer-patients-with-and-without-diabetes 2025-02-16T01:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/8efd7b72b2c983bd/fotivda-opdivo-combination-shows-comparable-quality-of-life-outcomes-to-fotivda-alone-in-advanced-kidney-cancer 2025-02-16T00:01:17+00:00 hourly 0.9 https://trial.medpath.com/news/c296ce916f47c3d8/eisai-seeks-japanese-approval-for-novel-fgfr-inhibitor-tasurgratinib-in-biliary-tract-cancer 2025-02-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1d7906be2068d54d/calypso-trial-savolitinib-durvalumab-combo-shows-promising-results-in-met-driven-papillary-renal-cancer 2025-02-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0ad84f6407265b9b/fda-approves-casgevy-for-beta-thalassemia-marking-second-indication-for-first-crispr-based-therapy 2025-02-15T23:31:10+00:00 hourly 0.9 https://trial.medpath.com/news/7814a6279b889953/cabozantinib-shows-promising-results-for-renal-cell-carcinoma-patients-with-brain-metastases-in-phase-2-trial 2025-02-15T22:32:26+00:00 hourly 0.9 https://trial.medpath.com/news/228997e499425960/novartis-s-oral-ms-drug-fty720-shows-promising-two-year-efficacy-data-potential-2010-launch 2025-02-15T22:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/24ae5741a8859c8a/fda-approved-fotivda-dose-shows-superior-efficacy-in-renal-cell-carcinoma-treatment 2025-02-15T22:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/6fb6a881b1882dce/ascension-alexian-brothers-hospital-launches-novel-alzheimer-s-treatment-trials-including-at-home-injectable-option 2025-02-15T22:31:11+00:00 hourly 0.9 https://trial.medpath.com/news/045486902e43a7ca/clear-trial-update-lenvatinib-pembrolizumab-combination-shows-sustained-efficacy-in-advanced-renal-cell-carcinoma 2025-02-15T19:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/1c4ecbbeacff2159/uva-launches-30m-trial-to-test-ketamine-for-life-threatening-seizures 2025-02-15T19:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/ab047d4b6dc3c88a/duke-scientists-develop-revolutionary-hydrogel-implant-surpassing-natural-knee-cartilage-strength 2025-02-15T16:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/477a8118827043b2/mediprint-s-weekly-glaucoma-contact-lens-shows-promise-in-phase-2b-trial-patents-secured-through-2043 2025-02-15T16:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/fc3911fc10197335/evolution-of-crs-and-icans-management-in-car-t-cell-therapy-new-consensus-guidelines-transform-treatment-approach 2025-02-15T15:39:49+00:00 hourly 0.9 https://trial.medpath.com/news/979c196877417c56/biostem-technologies-launches-pivotal-clinical-trial-for-vendaje-r-in-diabetic-foot-ulcer-treatment 2025-02-15T11:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/d5609637a78711b4/amgen-and-ideaya-terminate-cancer-combination-trial-for-prmt5-and-mat2a-inhibitors 2025-02-15T10:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/ea25d2094100cea5/edesa-biotech-advances-vitiligo-treatment-program-secures-15m-funding-for-eb06-development 2025-02-15T10:32:02+00:00 hourly 0.9 https://trial.medpath.com/news/33607294cd10ac89/anivive-completes-pivotal-field-trial-for-canine-lymphoma-drug-laverdia-ca1 2025-02-15T10:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/9a7a4b1a6ff4288c/fda-grants-orphan-drug-designation-to-opn-6602-for-relapsed-refractory-multiple-myeloma-treatment 2025-02-15T10:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/d1d68fca94671803/first-u-s-patient-receives-novel-nasal-spray-treatment-for-alzheimer-s-disease 2025-02-15T08:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/dcd85eb3c2640397/aptevo-s-alg-apv-527-shows-promise-in-solid-tumors-with-favorable-safety-profile-in-phase-1-trial 2025-02-15T08:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/f5324f72d88ae1c3/appili-therapeutics-advances-ati-1801-development-for-cutaneous-leishmaniasis-with-fda-alignment 2025-02-15T08:01:20+00:00 hourly 0.9 https://trial.medpath.com/news/f0829aa2746be93f/probiotic-supplementation-reduces-mortality-in-preterm-infants-canadian-study-shows 2025-02-15T07:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/e539d87eab89b5cc/phase-ii-trial-shows-breakthrough-63-6-response-rate-for-novel-bladder-cancer-combination-therapy 2025-02-15T07:31:49+00:00 hourly 0.9 https://trial.medpath.com/news/3c71a95b962c939b/first-ever-rct-to-evaluate-human-albumin-s-effectiveness-in-aneurysmal-subarachnoid-hemorrhage-launches-in-qatar 2025-02-15T07:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/e8ee7541e64075a7/expert-panel-updates-multiple-myeloma-maintenance-therapy-guidelines-focus-on-daratumumab-and-mrd-monitoring 2025-02-15T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3c91558bf83fcce8/enfortumab-vedotin-shows-promise-for-upper-tract-urothelial-cancer-patients-ineligible-for-standard-treatment 2025-02-15T05:31:15+00:00 hourly 0.9 https://trial.medpath.com/news/023d871b6e327db5/ucsf-performs-world-s-first-onq-prostate-assisted-robotic-hifu-procedure 2025-02-15T04:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/4bf7a06fff2fdff4/long-term-checkmate-214-data-highlights-need-for-biomarkers-in-metastatic-rcc-treatment-selection 2025-02-15T02:31:41+00:00 hourly 0.9 https://trial.medpath.com/news/663de14eb384940d/breakwater-trial-braftovi-erbitux-plus-chemotherapy-shows-promise-in-braf-v600e-metastatic-colorectal-cancer 2025-02-15T01:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/ad8fcf31a60eda0e/early-radiotherapy-side-effects-linked-to-long-term-complications-in-prostate-cancer-treatment 2025-02-15T01:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/6c166746cf54edf2/cosmic-313-trial-triplet-therapy-shows-mixed-results-in-advanced-renal-cell-carcinoma 2025-02-15T01:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/da59d5a8ffbe908e/sotagliflozin-shows-breakthrough-23-reduction-in-heart-attack-and-stroke-risk-for-diabetic-kidney-disease-patients 2025-02-15T01:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/34051fe3646e3c54/insulet-s-omnipod-5-demonstrates-significant-hba1c-reduction-in-type-2-diabetes-study 2025-02-15T01:31:15+00:00 hourly 0.9 https://trial.medpath.com/news/55aca311f446515a/zydus-lifesciences-topical-manufacturing-facility-achieves-perfect-fda-inspection-amid-strong-q3-performance 2025-02-15T00:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/fa6e39d9159f0497/phase-3-success-nefecon-shows-promise-in-treating-iga-nephropathy-filing-planned-for-early-2021 2025-02-15T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/009d8f719e6f8ebc/biogen-publishes-controversial-phase-3-aduhelm-trial-results-in-peer-reviewed-journal 2025-02-15T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/a042c6ec60996b2a/praxis-precision-medicines-stock-surges-as-analysts-maintain-strong-buy-ratings-for-cns-drug-developer 2025-02-15T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/6859ac793c69a9c3/sanofi-and-j-j-join-forces-in-175m-deal-to-combat-e-coli-sepsis-with-novel-vaccine 2025-02-14T23:31:13+00:00 hourly 0.9 https://trial.medpath.com/news/8b948fc1e5a52f0c/fda-halts-moderna-s-norovirus-vaccine-trial-following-guillain-barre-case 2025-02-14T22:35:35+00:00 hourly 0.9 https://trial.medpath.com/news/1ccfaaed11705155/fda-places-moderna-s-norovirus-vaccine-trial-on-clinical-hold-following-guillain-barre-case 2025-02-14T22:35:20+00:00 hourly 0.9 https://trial.medpath.com/news/b60848c643217ca3/peri-transplant-ruxolitinib-significantly-reduces-gvhd-risk-in-myelofibrosis-patients 2025-02-14T22:34:52+00:00 hourly 0.9 https://trial.medpath.com/news/bf39cdead6e6fa26/enfortumab-vedotin-shows-manageable-safety-profile-in-ultra-elderly-urothelial-cancer-patients 2025-02-14T22:34:25+00:00 hourly 0.9 https://trial.medpath.com/news/5751362541451e27/fda-approves-first-rapid-acting-insulin-biosimilar-merilog-for-diabetes-management 2025-02-14T22:34:03+00:00 hourly 0.9 https://trial.medpath.com/news/8dda82a002b155bb/adverse-events-linked-to-better-survival-outcomes-in-enfortumab-vedotin-treatment-for-urothelial-cancer 2025-02-14T22:33:35+00:00 hourly 0.9 https://trial.medpath.com/news/4eaff24a36aee055/fda-approves-vimseltinib-for-tenosynovial-giant-cell-tumor-treatment-showing-40-response-rate 2025-02-14T22:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/30378fd697146bb3/novel-radio-opaque-universal-adhesive-shows-promising-24-month-clinical-performance-in-cervical-restorations 2025-02-14T22:32:39+00:00 hourly 0.9 https://trial.medpath.com/news/dec60f78c0f0579c/algernon-neuroscience-launches-phase-2a-trial-of-dmt-for-stroke-recovery-with-leading-neurologist 2025-02-14T22:32:14+00:00 hourly 0.9 https://trial.medpath.com/news/132f03391915773d/naxitamab-shows-promising-results-in-treating-relapsed-refractory-high-risk-neuroblastoma 2025-02-14T22:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/08037b8ff0914cae/ai-guided-cardiac-ablation-shows-superior-results-in-landmark-persistent-af-trial 2025-02-14T21:01:21+00:00 hourly 0.9 https://trial.medpath.com/news/8e21c4fcf67595b2/omni-r-surgical-system-shows-long-term-efficacy-in-comprehensive-22-study-meta-analysis-for-glaucoma-treatment 2025-02-14T21:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/18970cdd48dbc1e6/phase-2-trial-evaluates-cabozantinib-as-neoadjuvant-therapy-for-locally-advanced-kidney-cancer 2025-02-14T20:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/7afb03ff911e89b5/groundbreaking-tourist-trial-aims-to-transform-stage-iv-lung-cancer-treatment-through-advanced-radiotherapy 2025-02-14T19:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/ce2658fa21e4a138/novel-magnetic-seizure-therapy-shows-promise-for-depression-treatment-with-fewer-cognitive-side-effects 2025-02-14T19:32:07+00:00 hourly 0.9 https://trial.medpath.com/news/946c48231b2ebad3/ai-guided-ablation-shows-superior-results-in-treating-persistent-atrial-fibrillation 2025-02-14T19:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/3ebb4916de8cf0ac/us-cardiovascular-clinical-trials-face-significant-enrollment-challenges-despite-high-site-numbers 2025-02-14T19:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/d2a258f4c3843176/fda-provides-positive-feedback-on-refluxstop-s-pma-module-2-for-acid-reflux-treatment 2025-02-14T18:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7c56521b21c3c5ea/vafidemstat-phase-iia-results-published-shows-promise-in-treating-psychiatric-aggression 2025-02-14T16:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/489d13198225e0c8/vistagen-advances-phase-3-trials-for-novel-social-anxiety-treatment-fasedienol-reports-positive-results-for-cancer-cachexia-drug 2025-02-14T16:32:46+00:00 hourly 0.9 https://trial.medpath.com/news/7fcf362230b4ba42/fda-grants-ind-approval-for-novel-inhaled-interferon-treatment-against-rsv-in-children 2025-02-14T16:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/b2e1488fadaa27f6/first-self-amplifying-mrna-covid-19-vaccine-kostaive-receives-european-commission-approval 2025-02-14T16:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/6a2c39112fa0a08f/study-reveals-low-adherence-to-breast-cancer-treatment-resumption-post-pregnancy 2025-02-14T16:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/0ef5e2eace7146a1/anakinra-fails-to-reduce-car-t-cell-therapy-complications-in-large-b-cell-lymphoma-trial 2025-02-14T16:31:16+00:00 hourly 0.9 https://trial.medpath.com/news/2a9f628c604a178e/xpovio-secures-public-health-insurance-coverage-in-taiwan-for-relapsed-refractory-multiple-myeloma 2025-02-14T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/45ca5da57b9bc5c7/ai-powered-mammography-shows-29-increase-in-cancer-detection-rate-paving-way-for-landmark-uk-trial 2025-02-14T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/23f10ccce1eac8f3/biocardia-completes-low-dose-cohort-enrollment-in-novel-cardiallo-trial-for-heart-failure-treatment 2025-02-14T13:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/6a951b236af02dd0/early-car-t-vector-load-assessment-using-idylla-platform-shows-promise-in-predicting-lbcl-treatment-outcomes 2025-02-14T13:31:17+00:00 hourly 0.9 https://trial.medpath.com/news/8bf78ed57d4a26f3/medicare-expands-coverage-for-alzheimer-s-drug-leqembi-setting-26500-annual-price-point 2025-02-14T13:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/8704c100520a6101/tevogen-bio-secures-in-house-cell-therapy-production-facility-to-accelerate-t-cell-therapeutics-development 2025-02-14T13:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/7efba45b188c4d4c/virpax-s-probudur-shows-promise-in-pain-management-studies-advancing-toward-ind-application 2025-02-14T12:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/e02900d6ddbc45be/experts-address-medical-mistrust-in-clinical-trials-building-trust-with-black-patients-through-understanding-and-communication 2025-02-14T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a5b4daedc1d8e57c/cell-and-gene-therapy-cdmo-market-set-to-reach-74-billion-by-2034-growing-at-28-cagr 2025-02-14T11:28:09+00:00 hourly 0.9 https://trial.medpath.com/news/14f4d4f303655f2e/study-shows-daa-therapy-matches-interferon-in-reducing-liver-cancer-risk-for-hcv-patients 2025-02-14T10:00:48+00:00 hourly 0.9 https://trial.medpath.com/news/1944b19259a93ecb/fda-approved-sezaby-shows-superior-efficacy-over-levetiracetam-for-neonatal-seizures 2025-02-14T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9e944ecc53b1c110/new-study-reveals-solar-urticaria-patterns-women-more-affected-uv-and-visible-light-key-triggers 2025-02-14T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1db796d0b93127c3/high-til-levels-could-enable-shorter-trastuzumab-treatment-in-early-erbb2-positive-breast-cancer 2025-02-14T08:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/b60e49074df75c8f/anacardio-secures-sek-205m-series-a-extension-and-reports-positive-heart-failure-drug-trial-results 2025-02-14T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/31e5a80856d0b3b8/dmd-market-set-to-more-than-double-to-5-2-billion-by-2033-driven-by-novel-therapies 2025-02-14T06:31:09+00:00 hourly 0.9 https://trial.medpath.com/news/8b06968936319b61/envoy-medical-expands-patent-portfolio-with-advanced-cochlear-implant-technologies 2025-02-14T06:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/b9364cffbefd6550/american-cancer-society-unveils-strategic-vision-517m-research-initiative-focuses-on-early-detection-and-diversity 2025-02-14T06:14:51+00:00 hourly 0.9 https://trial.medpath.com/news/a0fe03d06d21482a/studies-reveal-quality-of-life-trade-offs-with-androgen-deprivation-therapy-in-prostate-cancer-treatment 2025-02-14T06:13:36+00:00 hourly 0.9 https://trial.medpath.com/news/6272371f2654d7c4/stemspine-study-shows-90-reduction-in-opioid-use-for-chronic-back-pain-at-3-year-follow-up 2025-02-14T06:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/37e6bd4e0a5cf3f7/ash-2024-experts-highlight-promise-of-bispecific-antibodies-in-b-cell-lymphoma-treatment 2025-02-14T05:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/b0a842c48743c8ce/early-disease-progression-after-asct-in-young-patient-with-high-risk-multiple-myeloma-treatment-approaches 2025-02-14T05:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/74e678feda1848c4/five-critical-factors-for-heart-disease-prevention-new-comprehensive-analysis 2025-02-14T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a48bfe908a3cafcb/caredx-s-alloheme-test-shows-93-sensitivity-in-early-detection-of-aml-and-mds-relapse-post-transplant 2025-02-14T04:32:18+00:00 hourly 0.9 https://trial.medpath.com/news/6c3bf3c819506de8/personalized-cancer-vaccine-shows-promise-in-advanced-kidney-cancer-prevention 2025-02-14T04:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/b01c9f31bdab9e87/dalpiciclib-plus-letrozole-shows-promise-in-phase-ii-trial-for-hr-her2-breast-cancer 2025-02-14T04:31:34+00:00 hourly 0.9 https://trial.medpath.com/news/1d998df6c81c77f0/avecho-biotechnology-reports-potential-phase-iii-success-for-cbd-based-insomnia-treatment 2025-02-14T04:31:15+00:00 hourly 0.9 https://trial.medpath.com/news/a6b277ac163c132b/cdisc-and-lindus-health-partner-to-revolutionize-clinical-trial-data-standardization-using-ai 2025-02-14T03:23:48+00:00 hourly 0.9 https://trial.medpath.com/news/8549865a9d60e186/lilly-s-omvoh-shows-promising-two-year-remission-data-in-crohn-s-disease-patients 2025-02-14T03:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/88870588694122c9/eu-launches-revamped-hta-regulation-cancer-and-gene-therapies-first-in-line-for-joint-assessments 2025-02-14T02:56:46+00:00 hourly 0.9 https://trial.medpath.com/news/39302d64fc635041/expert-emphasizes-critical-need-for-comprehensive-ngs-testing-to-detect-her2-alterations-in-nsclc 2025-02-14T02:44:31+00:00 hourly 0.9 https://trial.medpath.com/news/73d069370be050fd/nexus-pharmaceuticals-secures-fda-approval-for-tacrolimus-injectable-formulation 2025-02-14T02:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/c6f6c34f929349b6/darolutamide-shows-consistent-benefits-across-age-groups-in-metastatic-prostate-cancer-arasens-trial-analysis 2025-02-14T01:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/bbb4c9f0f51e5b28/fda-approves-evolus-novel-hyaluronic-acid-dermal-fillers-with-superior-efficacy-profile 2025-02-14T01:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/e74a0bc419072de9/combined-therapy-doubles-smoking-cessation-success-in-hiv-patients-kenyan-trial-shows 2025-02-14T01:31:10+00:00 hourly 0.9 https://trial.medpath.com/news/0578cb8d7ea7ffb1/conduit-pharmaceuticals-partners-with-charles-river-to-advance-lupus-treatment-development 2025-02-14T00:26:32+00:00 hourly 0.9 https://trial.medpath.com/news/4243b0445219fa4b/fda-grants-broad-approval-for-gsk-s-ojjaara-in-myelofibrosis-with-anemia 2025-02-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/17f4cf64629ad26a/sandoz-s-denosumab-biosimilar-shows-promise-in-osteoporosis-trial-challenging-amgen-s-5b-franchise 2025-02-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f6bba589a3ff5405/first-in-class-il-4ra-st2-bispecific-antibody-ak139-advances-to-clinical-development-for-inflammatory-diseases 2025-02-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c177d8a0a300d67a/european-commission-approves-stelara-for-ulcerative-colitis-treatment 2025-02-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/da7db3f9c73a03c2/cms-completes-second-round-of-medicare-drug-price-negotiation-agreements-with-15-manufacturers 2025-02-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3635d3bd7f14b7e1/darolutamide-demonstrates-superior-benefits-in-black-and-white-patients-with-non-metastatic-prostate-cancer 2025-02-13T23:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/0e16c14c84c2a633/shilpa-medicare-s-novel-nafld-treatment-receives-cdsco-approval-following-successful-phase-3-trial 2025-02-13T23:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/74767e1ea9a7f910/nubeqa-shows-strong-efficacy-in-metastatic-prostate-cancer-subgroups-new-trial-data-reveals 2025-02-13T23:01:32+00:00 hourly 0.9 https://trial.medpath.com/news/dc45c67bd8efd095/allogene-s-car-t-cell-therapy-shows-promising-results-in-large-b-cell-lymphoma-trials 2025-02-13T23:01:09+00:00 hourly 0.9 https://trial.medpath.com/news/a05cda614016727f/phase-2-trial-shows-promising-results-for-cord-blood-transplantation-in-blood-cancer-patients 2025-02-13T22:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/6f2ddf91aec74809/bristol-myers-squibb-provides-update-on-phase-3-relativity-098-trial-for-lag-3-inhibitor 2025-02-13T22:31:33+00:00 hourly 0.9 https://trial.medpath.com/news/7874a94e912c025b/fda-fast-tracks-novel-drug-pp-01-for-cannabis-withdrawal-syndrome-treatment 2025-02-13T22:31:10+00:00 hourly 0.9 https://trial.medpath.com/news/1cb2d79ec0951179/puma-biotechnology-reports-strong-financial-performance-for-q4-and-full-year-2024 2025-02-13T21:40:48+00:00 hourly 0.9 https://trial.medpath.com/news/d02ae3c0f216301d/fda-grants-orphan-drug-designation-to-novartis-ianalumab-for-primary-immune-thrombocytopenia 2025-02-13T20:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/508f3df290baadb8/medicenna-reports-78-disease-control-rate-for-mdna11-keytruda-combination-in-advanced-cancer-trial 2025-02-13T20:01:12+00:00 hourly 0.9 https://trial.medpath.com/news/941b856a9b27bc80/pd-1-pd-l1-inhibitors-plus-chemotherapy-shows-improved-outcomes-in-asian-tnbc-patients 2025-02-13T19:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/ab8507254310beef/extended-interval-mammography-proven-safe-for-post-treatment-breast-cancer-surveillance 2025-02-13T19:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/59bde3da7bae0ac3/fda-guidance-enables-moleculin-to-streamline-phase-3-trial-for-novel-aml-treatment-annarac 2025-02-13T19:32:02+00:00 hourly 0.9 https://trial.medpath.com/news/de5ba0d856c0e274/newleos-launches-with-94m-series-a-and-roche-s-cns-portfolio-to-target-mental-health-disorders 2025-02-13T19:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/c7eb94b3874b8fa6/purplelab-study-reveals-critical-insights-into-u-s-migraine-treatment-patterns-and-healthcare-disparities 2025-02-13T19:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/63e29425e38eca1e/theralase-s-ruvidar-r-shows-complete-healing-of-hsv-1-lesions-in-preclinical-study 2025-02-13T17:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/094b3cf1f219fc44/whiteswell-s-elym-system-shows-promise-in-acute-heart-failure-fluid-management-trial 2025-02-13T16:36:39+00:00 hourly 0.9 https://trial.medpath.com/news/806fe960946738fa/phase-3-finesse-trial-launches-to-evaluate-finasteride-in-prostate-cancer-active-surveillance 2025-02-13T16:35:51+00:00 hourly 0.9 https://trial.medpath.com/news/fe88922cd721583b/agios-mitapivat-achieves-primary-endpoint-in-phase-3-trial-for-children-with-pk-deficiency 2025-02-13T16:35:23+00:00 hourly 0.9 https://trial.medpath.com/news/051c7e36daacf914/phase-2-trial-shows-promise-for-efzofitimod-in-reducing-steroid-dependence-in-sarcoidosis-patients 2025-02-13T16:35:01+00:00 hourly 0.9 https://trial.medpath.com/news/60495a57756a9f84/talapro-2-trial-talazoparib-enzalutamide-combo-shows-significant-survival-benefit-in-metastatic-prostate-cancer 2025-02-13T16:34:35+00:00 hourly 0.9 https://trial.medpath.com/news/580f53441102ff6e/maastricht-umc-develops-promising-drug-for-hereditary-fructose-intolerance-treatment 2025-02-13T16:34:15+00:00 hourly 0.9 https://trial.medpath.com/news/cc3312557cd78028/indian-scientists-develop-revolutionary-liver-support-system-for-acute-liver-failure-treatment 2025-02-13T16:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/e47e65c5906c4616/fda-clears-novel-electronic-patch-for-premature-ejaculation-treatment 2025-02-13T16:33:27+00:00 hourly 0.9 https://trial.medpath.com/news/328f70dcdf096352/healthbio-launches-fda-fast-track-trial-for-long-covid-treatment-using-maraviroc-atorvastatin-combination 2025-02-13T16:33:02+00:00 hourly 0.9 https://trial.medpath.com/news/65fb15fc9af7c2ec/ozempic-shows-promise-in-reducing-alcohol-consumption-trial-reveals-40-decrease 2025-02-13T16:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/1aa5618dc58efb6c/island-pharmaceuticals-completes-patient-dosing-in-phase-2b-protect-trial-for-dengue-fever-treatment 2025-02-13T16:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/ac7db3fc3f572721/uk-first-study-on-pediatric-brain-trauma-features-remarkable-recovery-of-12-year-old-quad-bike-accident-survivor 2025-02-13T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/94d2b28c64652f1d/bio-rad-to-acquire-stilla-technologies-expanding-digital-pcr-portfolio 2025-02-13T15:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/8fd4d21ad54dadce/fda-grants-rmat-designation-to-elixirgen-s-novel-gene-therapy-for-rare-telomere-disorders 2025-02-13T14:31:09+00:00 hourly 0.9 https://trial.medpath.com/news/5f56e9eb4dd258c4/study-reveals-critical-gaps-in-genetic-testing-and-parp-inhibitor-treatment-for-advanced-prostate-cancer 2025-02-13T14:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/1cf9c2f038f0096b/subtle-medical-secures-fda-clearance-and-ce-mark-for-subtlehdtm-revolutionizing-mri-imaging-speed-and-quality 2025-02-13T14:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/064bcb11c5692af7/telix-pharmaceuticals-to-present-advanced-prostate-and-kidney-cancer-therapies-at-asco-gu-2025 2025-02-13T14:01:15+00:00 hourly 0.9 https://trial.medpath.com/news/6d2d50a911282de1/blood-volume-analysis-outperforms-traditional-methods-in-heart-failure-assessment-multicenter-study-shows 2025-02-13T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7c95abf27a327eaf/ideaya-biosciences-reports-strong-pipeline-progress-and-1-1b-cash-position-for-2024 2025-02-13T13:31:58+00:00 hourly 0.9 https://trial.medpath.com/news/8fa0e753d710fdcc/new-analysis-shows-next-gen-alzheimer-s-drugs-add-8-10-months-of-independent-living 2025-02-13T13:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/c1d5f9842471508f/novel-lion-trial-combines-anti-inflammatory-drug-with-immunotherapy-to-combat-advanced-cancers 2025-02-13T13:31:11+00:00 hourly 0.9 https://trial.medpath.com/news/c7b95b3da1bac0b5/deepmind-alphafold-veteran-raises-50m-to-launch-ai-powered-protein-design-platform 2025-02-13T13:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/7a6a2095b2dea010/ideaya-and-amgen-discontinue-ide397-amg-193-combination-study-despite-promising-preclinical-data 2025-02-13T12:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/4ff62a3b52cf5333/glenmark-launches-generic-clindamycin-phosphate-foam-for-dermatological-treatment 2025-02-13T12:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/ca4904c89ccc96a9/cost-and-implementation-barriers-challenge-adoption-of-novel-muc-therapies-asco-gu-studies-show 2025-02-13T11:42:27+00:00 hourly 0.9 https://trial.medpath.com/news/6a3171071f7bbf42/ipsen-advances-pipeline-with-multiple-regulatory-wins-and-strategic-partnerships-in-2024 2025-02-13T11:01:10+00:00 hourly 0.9 https://trial.medpath.com/news/c96faa2ecbd3224f/precision-medicine-and-ai-drive-major-advances-in-cancer-treatment-outcomes 2025-02-13T10:45:33+00:00 hourly 0.9 https://trial.medpath.com/news/46227db92d586fef/torrent-capital-secures-8-75m-financing-to-expand-cryptocurrency-investment-portfolio 2025-02-13T10:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/6209d863af4ebd6c/pfizer-biontech-launches-landmark-phase-3-trial-for-mrna-based-influenza-vaccine 2025-02-13T10:32:58+00:00 hourly 0.9 https://trial.medpath.com/news/fe0e1d9ace53df63/first-patient-dosed-in-groundbreaking-optogenetic-gene-therapy-trial-for-retinitis-pigmentosa 2025-02-13T10:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/8aebb333a4f18600/bioarctic-signs-1-35-billion-deal-with-bms-reports-growing-leqembi-sales-in-q4-2024 2025-02-13T10:32:11+00:00 hourly 0.9 https://trial.medpath.com/news/c0f3a3763df4e2a8/sanofi-and-j-j-halt-phase-3-trial-of-e-coli-vaccine-due-to-insufficient-efficacy 2025-02-13T10:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/1e1b8f91bcf5b0e9/phase-3-hope-trial-tests-novel-light-sound-therapy-device-for-moderate-alzheimer-s-treatment 2025-02-13T10:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/5ea64361519fd5c8/scotiabank-raises-travere-therapeutics-price-target-following-planned-filspari-snda-filing 2025-02-13T10:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/1ea6845db6d2547d/odiot-holding-secures-eur2-16m-capital-raise-to-expand-luxury-silversmith-operations 2025-02-13T08:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/dda5fed35659be10/cognito-therapeutics-expands-leadership-team-with-four-key-executive-appointments-ahead-of-alzheimer-s-treatment-launch 2025-02-13T08:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/23ee387f840ae30f/novel-cdk2-inhibitor-inx-315-shows-promise-in-overcoming-cancer-drug-resistance-study-reveals 2025-02-13T08:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/dc6791f4ed92c333/nih-funding-cuts-under-trump-administration-threaten-early-stage-biopharma-innovation 2025-02-13T07:44:28+00:00 hourly 0.9 https://trial.medpath.com/news/b1a4742dac40996d/novel-briovad-heart-pump-begins-clinical-trial-at-university-of-michigan-challenging-heartmate-3-s-market-dominance 2025-02-13T07:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/15a58ddf8fa219da/pipeline-for-pulmonary-arterial-hypertension-treatment-expands-with-55-companies-developing-novel-therapies 2025-02-13T07:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/d4f710f606783953/groundbreaking-uk-study-advances-treatment-monitoring-for-pediatric-traumatic-brain-injuries 2025-02-13T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e0ed509074d8ff4a/black-women-significantly-underrepresented-in-triple-negative-breast-cancer-clinical-trials-despite-higher-disease-burden 2025-02-13T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ab612a97b91751e7/watchman-device-shows-promise-for-afib-patients-seeking-alternatives-to-blood-thinners 2025-02-13T05:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/b109927d2e33cde0/esketamine-shows-promise-in-small-pilot-trial-for-rett-syndrome-symptoms 2025-02-13T04:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/f273588cca922c3f/survaxm-glioblastoma-trial-advances-following-positive-interim-analysis 2025-02-13T04:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/badf663506752995/selkirk-pharma-launches-clinfast-service-to-accelerate-clinical-trial-material-production 2025-02-13T03:04:53+00:00 hourly 0.9 https://trial.medpath.com/news/b4e8dac39fd76ab8/phase-3-trial-shows-promising-results-for-novel-encapsulated-cell-therapy-in-mactel-treatment 2025-02-13T02:31:13+00:00 hourly 0.9 https://trial.medpath.com/news/d34c0344c8afd1bf/advanced-technologies-and-modular-design-revolutionize-pharmaceutical-facility-construction 2025-02-13T02:02:52+00:00 hourly 0.9 https://trial.medpath.com/news/7ed5e0035be974af/fda-approves-voranigo-first-targeted-therapy-for-idh-mutant-glioma-brain-cancer 2025-02-13T01:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/23fa146697b9d97a/evolving-cervical-cancer-treatment-landscape-surgical-approaches-and-immunotherapy-sequencing-take-center-stage 2025-02-13T01:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/51a09384d1c8e005/novel-magshapetm-microcapsules-show-superior-magnesium-absorption-in-clinical-trial 2025-02-13T01:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/2c1f1c57d9d932fa/minimalist-dna-hydrogel-shows-promise-for-sustained-drug-delivery-with-improved-retention 2025-02-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/235604b7dd76f4f0/apple-launches-landmark-5-year-health-study-to-explore-technology-s-impact-on-wellbeing 2025-02-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2ad14404b2a10dcc/japan-approves-groundbreaking-viral-therapy-teserpaturev-for-glioblastoma-treatment 2025-02-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ec1aecc5c2fedaae/novel-radioligand-therapy-shows-complete-response-in-muscle-invasive-bladder-cancer-patient 2025-02-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/97913074e8430155/neumora-therapeutics-announces-major-leadership-restructuring-as-paul-berns-takes-ceo-role 2025-02-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/89e3f0774f4c8609/manchester-s-pill-connect-secures-investment-to-revolutionize-clinical-trial-drug-adherence-tracking 2025-02-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b272b658c0e4d1dd/galapagos-reports-strong-clinical-results-for-cell-therapy-program-plans-strategic-split-into-two-companies 2025-02-12T22:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/ca35c17e73097b33/novel-gene-silencing-therapy-shows-promise-for-long-term-cholesterol-control-with-single-dose 2025-02-12T22:32:02+00:00 hourly 0.9 https://trial.medpath.com/news/ce7159795fb0a0b1/ipsen-s-sohonos-becomes-first-approved-treatment-for-fop-in-canada 2025-02-12T22:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/57fe4eecf5e8d11f/long-term-ease-trial-shows-promise-birch-triterpenes-demonstrates-sustained-wound-reduction-in-epidermolysis-bullosa-patients 2025-02-12T22:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/186f43ae9c8e6762/anaptysbio-s-phase-2b-rheumatoid-arthritis-trial-results-face-scrutiny-over-placebo-handling 2025-02-12T20:01:23+00:00 hourly 0.9 https://trial.medpath.com/news/818d92d16bc2325e/novel-car-t-trial-aims-to-prevent-recurrence-in-aggressive-b-cell-lymphoma-patients 2025-02-12T19:33:19+00:00 hourly 0.9 https://trial.medpath.com/news/69e2965b49026362/maxona-s-novel-non-opioid-pain-therapy-max-001-successfully-completes-phase-1-trials 2025-02-12T19:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/ee67804d9bc8df34/abcuro-secures-200m-series-c-funding-to-advance-novel-ibm-treatment-ulviprubart 2025-02-12T19:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/5488de114ad02da7/fda-expands-adcetris-approval-for-relapsed-large-b-cell-lymphoma-treatment 2025-02-12T19:32:06+00:00 hourly 0.9 https://trial.medpath.com/news/c087ae141b40291f/dana-farber-researchers-to-present-groundbreaking-cellular-therapy-studies-at-2025-tandem-meetings 2025-02-12T19:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/73b5a5296b8279fb/clinical-trial-to-evaluate-dexamethasone-implant-with-vitrectomy-for-proliferative-diabetic-retinopathy 2025-02-12T19:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/9e50a3211086b271/zydus-lifesciences-partners-with-synthon-for-novel-cancer-drug-development-in-1-5-billion-us-market 2025-02-12T18:24:03+00:00 hourly 0.9 https://trial.medpath.com/news/3e080e0facce2eb2/novel-approach-converting-parallel-cluster-trials-to-stepped-wedge-design-shows-promise-in-global-health-research 2025-02-12T18:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/2f2aed6d6a1bb679/biogen-faces-critical-q4-earnings-report-amid-leqembi-challenges-and-strategic-developments 2025-02-12T17:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/b0174b749a2c1087/seaport-therapeutics-secures-225m-series-b-to-advance-novel-neuropsychiatric-drug-pipeline 2025-02-12T17:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/f9f82e3e92fff7fa/experts-explore-hierarchical-composite-endpoints-to-transform-nephrology-clinical-trials 2025-02-12T17:01:12+00:00 hourly 0.9 https://trial.medpath.com/news/53b8baaf761a304c/tivic-health-acquires-late-stage-radiation-treatment-entolimod-expanding-into-immunotherapy 2025-02-12T16:36:38+00:00 hourly 0.9 https://trial.medpath.com/news/f7dfdd4c52e1cdf9/biogen-secures-250m-from-royalty-pharma-to-advance-lupus-antibody-into-phase-iii-trials 2025-02-12T16:36:17+00:00 hourly 0.9 https://trial.medpath.com/news/34b84422d021d824/fda-grants-fast-track-status-to-oncusp-s-novel-antibody-drug-conjugate-for-platinum-resistant-ovarian-cancer 2025-02-12T16:35:55+00:00 hourly 0.9 https://trial.medpath.com/news/e23b95755f174f97/nih-funded-research-drives-breakthrough-in-cystic-fibrosis-treatment-with-trikafta 2025-02-12T16:35:35+00:00 hourly 0.9 https://trial.medpath.com/news/7f2d3d959536d5f1/fda-grants-fast-track-status-to-nkgen-s-nk-cell-therapy-troculeucel-for-moderate-alzheimer-s-disease 2025-02-12T16:35:18+00:00 hourly 0.9 https://trial.medpath.com/news/ae8c924413832d81/zolgensma-s-journey-from-2m-charity-funded-research-to-world-s-most-expensive-drug 2025-02-12T16:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/dbfed7c66955e331/uva-initiates-clinical-trial-of-ai-enhanced-automated-insulin-delivery-system-for-type-1-diabetes 2025-02-12T16:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/447f5880f2d5479f/irlab-reports-strong-progress-in-parkinson-s-drug-development-pipeline-with-multiple-clinical-milestones 2025-02-12T14:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/d2fb07ac6e102499/rosnilimab-shows-breakthrough-results-in-phase-2b-rheumatoid-arthritis-trial-with-record-setting-disease-control 2025-02-12T14:01:24+00:00 hourly 0.9 https://trial.medpath.com/news/5c3a68e62533f6e8/crispr-therapeutics-casgevy-launch-shows-steady-progress-amid-cautious-market-outlook 2025-02-12T13:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/b808c259a3685289/inmune-bio-advances-to-phase-ii-trial-of-inkmunetm-therapy-for-metastatic-prostate-cancer 2025-02-12T13:31:47+00:00 hourly 0.9 https://trial.medpath.com/news/415526b7d2391582/novel-gold-nanorod-therapy-shows-promise-for-cold-tumor-treatment-to-be-presented-at-canadian-melanoma-conference 2025-02-12T13:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/69a2b18dee66d44d/new-evaluation-system-shows-promise-in-reducing-unnecessary-hospital-stays-for-colorectal-cancer-patients 2025-02-12T12:35:36+00:00 hourly 0.9 https://trial.medpath.com/news/b01f65ba9a4add90/gender-gap-widens-in-hiv-life-expectancy-women-face-significant-disparities-despite-overall-improvements 2025-02-12T10:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/194e7d02c6d4dee2/bicara-launches-pivotal-phase-2-3-trial-of-novel-bifunctional-antibody-for-advanced-head-and-neck-cancer 2025-02-12T10:32:11+00:00 hourly 0.9 https://trial.medpath.com/news/32e653c45faeb929/fda-delays-review-of-sublocade-label-changes-for-opioid-use-disorder-treatment 2025-02-12T10:31:56+00:00 hourly 0.9 https://trial.medpath.com/news/aac0471b8215ae57/nih-collaboratory-trial-evaluates-novel-advance-care-planning-program-for-elderly-cancer-patients 2025-02-12T10:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/b5ae1c562e03d513/bluejay-therapeutics-strengthens-leadership-team-with-appointment-of-veteran-biotech-executive-mary-cromwell 2025-02-12T08:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/997b91cdf184ee0e/china-overtakes-us-as-global-leader-in-clinical-trial-volume-globaldata-analysis-reveals 2025-02-12T08:21:41+00:00 hourly 0.9 https://trial.medpath.com/news/b4cbe7cead3fe068/aligos-therapeutics-secures-105m-financing-to-advance-hepatitis-b-drug-development 2025-02-12T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2e9226f401283a80/uniqure-launches-public-offering-to-advance-gene-therapy-pipeline 2025-02-12T05:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/1df9630967b58437/arcus-biosciences-to-present-casdatifan-monotherapy-data-in-advanced-kidney-cancer-at-asco-gu-2025 2025-02-12T05:31:33+00:00 hourly 0.9 https://trial.medpath.com/news/29c92b9e1ad8e36f/terrain-biosciences-launches-ai-powered-rna-design-platform-with-9m-seed-funding 2025-02-12T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/941ccc2545baa5b0/university-of-alberta-s-novel-cancer-drug-zelenirstat-receives-fda-fast-track-designation 2025-02-12T04:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/c7f8ae770c9e987a/fda-clears-lion-tcr-s-novel-mrna-based-tcr-t-cell-therapy-for-phase-2-trial-in-hbv-related-liver-cancer 2025-02-12T04:31:41+00:00 hourly 0.9 https://trial.medpath.com/news/3f783fee020df24f/alexion-launches-interactive-storybook-to-help-children-understand-rare-kidney-disease-ahus 2025-02-12T03:45:27+00:00 hourly 0.9 https://trial.medpath.com/news/381ed0861ec99a5e/biolab-holdings-advances-venous-leg-ulcer-treatment-with-irb-approval-for-membrane-wrap-trial 2025-02-12T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/87c2345bddb67066/voyager-therapeutics-redirects-sod1-als-gene-therapy-development-after-preclinical-findings 2025-02-12T01:32:27+00:00 hourly 0.9 https://trial.medpath.com/news/66fe90d211803dd1/nih-study-single-dose-of-medi8852-antibody-shows-complete-protection-against-h5n1-avian-flu-in-primates 2025-02-12T01:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/32fa3dc1060e8f77/incyte-faces-market-uncertainty-as-povorcitinib-phase-iii-trial-results-loom 2025-02-12T01:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/0f4cf4f3ed4d9edc/inventiva-slashes-workforce-and-programs-to-focus-on-late-stage-mash-drug-lanifibranor 2025-02-12T01:31:34+00:00 hourly 0.9 https://trial.medpath.com/news/ded6ce4d0d78f744/phase-1-trial-shows-promise-for-in-006-inhaled-covid-19-antibody-therapy 2025-02-12T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/ca0aae68ff88ef9c/european-study-shows-biosimilar-competition-drives-21-6-reduction-in-insulin-glargine-prices 2025-02-12T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/acb77d951e28cefb/travere-therapeutics-plans-snda-submission-for-filspari-to-treat-rare-kidney-disease-fsgs 2025-02-11T22:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/3221093e1f4d8118/ausperbio-completes-dosing-in-phase-iib-trial-of-novel-hepatitis-b-treatment-ahb-137 2025-02-11T22:32:36+00:00 hourly 0.9 https://trial.medpath.com/news/66a4163fdbde90bc/bleximenib-shows-promising-results-in-advanced-acute-leukemia-trial-with-kmt2a-and-npm1-mutations 2025-02-11T22:32:11+00:00 hourly 0.9 https://trial.medpath.com/news/53ecf363ddc10af5/global-neuroregeneration-therapy-market-set-to-reach-64-8-billion-by-2034-driven-by-ai-and-stem-cell-innovations 2025-02-11T22:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/b005dedb1c2c4e0e/uc-davis-brain-computer-interface-achieves-97-accuracy-in-speech-translation-wins-top-clinical-research-award 2025-02-11T22:31:21+00:00 hourly 0.9